[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 23432
1. Koplay M, Kantarci M, Güven F, Aksoy Y, Taser F, Ziypak T, Eren S, Levent A, Atamanalp SS: Diagnostic efficiency of multidetector computed tomography with multiplanar reformatted imaging and virtual cystoscopy in the assessment of bladder tumors after transurethral resection. J Comput Assist Tomogr; 2010 Jan;34(1):121-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic efficiency of multidetector computed tomography with multiplanar reformatted imaging and virtual cystoscopy in the assessment of bladder tumors after transurethral resection.
  • PURPOSE: In the assessment of recurrent bladder tumors, diagnostic efficiency of virtual cystoscopy carried out by multidetector computed tomography (MDCT) was investigated and compared with the criterion standard of conventional cystoscopy.
  • MATERIALS AND METHODS: Twenty-seven patients between 39 and 83 years who had undergone transurethral resection because of bladder tumors were assessed using virtual and conventional cystoscopy.
  • RESULTS: For bladder pathologies, the sensitivity and specificity of CT cystography coupled with virtual cystoscopy were 91% and 92%, respectively.
  • In addition to bladder pathologies, we investigated liver metastases, kidney cysts, fluid in abdomen, and lymphadenopathies.
  • CONCLUSIONS: Using MDCT with virtual cystoscopy to assess primary bladder tumors and, in particular, to determine tumor recurrence after transurethral resection is a minimally invasive method that can be used in the long-term follow-up care of patients.
  • [MeSH-major] Cystoscopy / methods. Neoplasm Recurrence, Local / radiography. Tomography, X-Ray Computed / methods. Urethra / surgery. Urinary Bladder Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted / methods. Male. Middle Aged. Observer Variation. Radiographic Image Enhancement / methods. Sensitivity and Specificity. Urinary Bladder / radiography. Urologic Surgical Procedures / methods. User-Computer Interface

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118734.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


2. Loran OB, Shvalev VN, Pisarev SA, Kleĭmenova NV, Sukhorukov VS: [Mast cells and innervation of the wall of the hyperactive urinary bladder]. Arkh Patol; 2007 Nov-Dec;69(6):29-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mast cells and innervation of the wall of the hyperactive urinary bladder].
  • Anterior urinary bladder wall biopsy specimens were examined in 24 males and 4 females, aged 52 to 76 years, who had been suffering from the hyperactive urinary bladder for 1-10 years.
  • [MeSH-major] Mast Cells / physiology. Urinary Bladder / innervation. Urinary Bladder, Overactive / pathology

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18290377.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


3. Sung W, Park BD, Lee S, Chang SG: Villous adenoma of the urinary bladder. Int J Urol; 2008 Jun;15(6):551-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villous adenoma of the urinary bladder.
  • Villous adenomas arising in the urinary tract are an uncommon occurrence.
  • They have been identified in the urachus, urethra, prostate, and throughout the bladder.
  • Villous adenomas arising in the bladder are rare tumors that have been described as isolated cases and a few case series.
  • We report a new case of a large villous adenoma arising in the bladder that was treated by transurethral resection.
  • [MeSH-major] Adenoma, Villous / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489648.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


Advertisement
4. Mao Q, Lin Y, Zheng X, Qin J, Yang K, Xie L: A meta-analysis of alcohol intake and risk of bladder cancer. Cancer Causes Control; 2010 Nov;21(11):1843-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A meta-analysis of alcohol intake and risk of bladder cancer.
  • OBJECTIVE: Epidemiologic studies have reported conflicting results relating alcohol intake to bladder cancer risk.
  • A meta-analysis of cohort and case-control studies was conducted to pool the risk estimates of the association between alcohol intake and bladder cancer.
  • No association with bladder cancer was observed in either overall alcohol intake group (OR = 1.00, 95% CI 0.89-1.10) or subgroups stratified by sex, study design, geographical region, or smoking status.
  • However, in the analysis by specific beverages, both beer (OR = 0.86, 95% CI 0.76-0.96) and wine (OR = 0.85, 95% CI 0.71-1.00) consumption exhibited a negative dose-response relationship with bladder cancer.
  • CONCLUSION: The overall current literature on alcohol consumption and the risk of bladder cancer suggested no association, while the consumption of beer and wine was associated with reduced risk of bladder cancer.
  • [MeSH-major] Alcohol Drinking / adverse effects. Meta-Analysis as Topic. Urinary Bladder Neoplasms / epidemiology


5. Leung UC, Wong PY, Roberts RH, Koea JB: Gall bladder polyps in sclerosing cholangitis: does the 1-cm rule apply? ANZ J Surg; 2007 May;77(5):355-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gall bladder polyps in sclerosing cholangitis: does the 1-cm rule apply?
  • INTRODUCTION: Polyps of the gall bladder (PLG) are common findings in radiological investigations of the gall bladder and most are benign although carcinoma of the gall bladder can arise in PLG.
  • METHODS: All patients undergoing surgical resection for gall bladder cancer were entered into a prospective database.
  • Four patients with primary sclerosing cholangitis (PSC) presenting with gall bladder cancer in a PLG are studied.
  • Tumour markers carcinoembryonic antigen and CA19-9 were within the normal range in all patients.
  • Two patients with T1 tumours remain alive and well at 2 and 4 years post-cholecystectomy.
  • Of the remaining two patients with T2 tumours, one underwent re-resection of the liver bed and portal lymph nodes and remains alive and well at 12 months.
  • CONCLUSION: Gall bladder polyps, which are common and are usually benign in the general population, are often malignant in PSC.
  • [MeSH-major] Carcinoma / diagnosis. Cholangitis, Sclerosing / complications. Gallbladder Diseases / radiography. Gallbladder Neoplasms / diagnosis. Polyps / radiography

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497975.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


6. Ansari SM, Banu S, Awal MA, Siddique AB, Alam MM: Polypoid gall bladder lesions: is it necessary for immediate surgery? Bangladesh Med Res Counc Bull; 2007 Aug;33(2):44-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polypoid gall bladder lesions: is it necessary for immediate surgery?
  • A total of 57 patients with polypoid lesions in gall bladder were diagnosed and underwent extensive follow-up.
  • In 31 patients, who underwent surgery, the histological findings were cholesterol polyp/cholesterosis (n=14), cholesterosis with fibrous displasia of gall bladder (n=7), adenomyomatosis (n=3), hyperplastic cholecystosis (n=5) and adenocarcinoma (n=2).
  • Remaining 26 patients were under follow-up up to 18 months from first diagnosis.
  • Though most of the polyps diagnosed on ultrasound appeared to be benign without any risk of malignant transformation, it, however, may be recommended to go for surgery in a persistent symptomatic patient.

  • MedlinePlus Health Information. consumer health - Gallbladder Diseases.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18481437.001).
  • [ISSN] 0377-9238
  • [Journal-full-title] Bangladesh Medical Research Council bulletin
  • [ISO-abbreviation] Bangladesh Med Res Counc Bull
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bangladesh
  • [Chemical-registry-number] 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


7. Leclers F, Mourey E, Galas JM, Cormier L, Mangin P: [Cystomanometric study of bladder sensation during sacral neuromodulation test]. Prog Urol; 2005 Apr;15(2):238-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cystomanometric study of bladder sensation during sacral neuromodulation test].
  • [Transliterated title] Etude cystomanométrique de la sensation vésicale pendant le test de neuromodulation sacrée.
  • PURPOSE: Prospective clinical and urodynamic study evaluating modification of bladder sensation during sacral neuromodulation (SNM).
  • MATERIALS AND METHODS: 24 consecutive patients with non-neurological hyperactive bladder underwent an SNM test.
  • Questioned about their symptoms before and during the test by the urinary handicap assessment scale, patients were divided into two groups: A (improved) and B (not improved).
  • Urodynamic assessment in group A during the test demonstrated a significant increase of +23% of bladder capacity (p<0.01), +57% of the volume of onset of the first unstable contraction (p<0.004), +83% of bladder volume to the first urge to urinate BI (p<0.001) and +46% to urgency B3 (p<0.04).
  • During SNM, cystometry revealed that 1 or 2 bladder filling volumes were increased at B1 and/or B3 in 100% of improved subjects.
  • Our results suggest the use of the cystomanometric increase of bladder volume at B1 and B3 as selection criterion for candidates for SNM with non-neurological hyperactive bladder.
  • [MeSH-major] Sensation. Urinary Incontinence / physiopathology

  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999600.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


8. Kaneda T, Watanabe A, Shimizu K, Urakawa N, Nakajyo S: Effects of various selective phosphodiesterase inhibitors on carbachol-induced contraction and cyclic nucleotide contents in the guinea pig gall bladder. J Vet Med Sci; 2005 Jul;67(7):659-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of various selective phosphodiesterase inhibitors on carbachol-induced contraction and cyclic nucleotide contents in the guinea pig gall bladder.
  • The effects of various selective phosphodiesterase (PDE) inhibitors on muscle contractility and cyclic nucleotide contents in the guinea pig gall bladder were investigated.
  • The rank order of potency for the gall bladder was Ro20-1724 > vinpocetine > EHNA > milrinone > zaprinast, which was different from that of the trachea, taenia coli, and aorta.
  • These results suggest that vinpocetine-, milrinone-, and Ro20-1724-induced relaxation was correlated with cAMP, zaprinast-induced relaxation was correlated with cGMP, and that EHNA-induced relaxation was correlated with cAMP and cGMP in the guinea pig gall bladder.
  • In conclusion, the effect of PDE inhibitors in the guinea pig gall bladder was different from those in smooth muscles, such as the trachea, taenia coli, and aorta.

  • Hazardous Substances Data Bank. CARBACHOL CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16082113.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nucleotides, Cyclic; 0 / Phosphodiesterase Inhibitors; 0 / Purinones; 0 / Vinca Alkaloids; 29925-17-5 / 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; 543512OBTC / vinpocetine; 59262-86-1 / 9-(2-hydroxy-3-nonyl)adenine; 8Y164V895Y / Carbachol; E0399OZS9N / Cyclic AMP; GXT25D5DS0 / zaprinast; H2D2X058MU / Cyclic GMP; JAC85A2161 / Adenine; JU9YAX04C7 / Milrinone
  •  go-up   go-down


9. Theoharides TC, Whitmore K, Stanford E, Moldwin R, O'Leary MP: Interstitial cystitis: bladder pain and beyond. Expert Opin Pharmacother; 2008 Dec;9(17):2979-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interstitial cystitis: bladder pain and beyond.
  • BACKGROUND: Interstitial cystitis is characterized by over 6 months of chronic pain, pressure and discomfort felt in the lower pelvis or bladder.
  • It is often relieved with voiding, along with daytime frequency and nocturia in the absence of a urinary tract infection.
  • Interstitial cystitis occurs primarily in females including adolescents and its diagnosis is still one of exclusion.
  • Oral or intravesical administration of solutions containing sodium hyaluronate, chondroitin sulfate and quercetin to both reduce bladder inflammation and 'replenish' the glycosaminoglycan layer should be tried.

  • Genetic Alliance. consumer health - Interstitial cystitis.
  • MedlinePlus Health Information. consumer health - Interstitial Cystitis.
  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19006474.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR47652; United States / NIDDK NIH HHS / DK / DK30102; United States / NIDDK NIH HHS / DK / DK42409; United States / NIDDK NIH HHS / DK / DK44816; United States / NIDDK NIH HHS / DK / DK54133; United States / NIDDK NIH HHS / DK / DK62861; United States / NIDDK NIH HHS / DK / DK63652; United States / NIDDK NIH HHS / DK / DK65244; United States / NINDS NIH HHS / NS / NS38326; United States / NIDDK NIH HHS / DK / UO1 DK065187
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 161
  •  go-up   go-down


10. Nanda MS, Sameer AS, Syeed N, Shah ZA, Murtaza I, Siddiqi MA, Ali A: Genetic aberrations of the K-ras proto-oncogene in bladder cancer in Kashmiri population. Urol J; 2010;7(3):168-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic aberrations of the K-ras proto-oncogene in bladder cancer in Kashmiri population.
  • PURPOSE: To assess the frequency of specific point mutations in the K-ras gene in a group of Kashmiri patients with bladder cancer.
  • MATERIALS AND METHODS: We analyzed the incidence of K-ras exon 1 gene mutations in tumors and surgical margins in 60 patients with transitional cell carcinoma of varied clinical stages and histological grades using the polymerase chain reaction-single strand conformation polymorphism and DNA sequencing.
  • RESULTS: A significant correlation was found between the K-ras, the lymph node status, and tumor recurrence (P < 0.05).
  • Also, smokers and patients with higher tumor grade showed a significantly higher relative risk of developing K-ras mutations than the normal ones.
  • CONCLUSION: K-ras exon 1 gene mutations were found with low frequency in the bladder cancer tumors from Kashmir valley, which suggests that K-ras gene might be involved in a sub-set of bladder tumors, but it needs further investigation on a larger cohort sample to authenticate the current findings.
  • [MeSH-major] Carcinoma, Transitional Cell / genetics. Chromosome Aberrations. DNA, Neoplasm / genetics. Genes, ras / genetics. Mutation. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20845292.001).
  • [ISSN] 1735-546X
  • [Journal-full-title] Urology journal
  • [ISO-abbreviation] Urol J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


11. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y: Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer; 2007 Mar 15;109(6):1106-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin expression is associated with bladder cancer presence, stage, progression, and mortality.
  • BACKGROUND: The purpose was to compare the differential expression of Survivin in normal bladder tissue, bladder transitional cell carcinoma (TCC) of different stages, and to determine whether expression of Survivin is associated with TCC clinical outcomes.
  • METHODS: Immunohistochemical staining for Survivin was carried out on archival bladder specimens from 9 normal controls and 222 consecutive patients who underwent radical cystectomy and bilateral lymphadenectomy.
  • RESULTS: Survivin was expressed in none of the normal bladder specimens, 64% of the cystectomy specimens, and 94% of the malignant lymph nodes.
  • CONCLUSIONS: The findings of the study provide a rationale for further evaluation of Survivin and its downstream signaling pathways in bladder cancer and raise the potential for Survivin-targeted therapy for bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / pathology. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cystectomy. Disease Progression. Female. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17311310.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


12. Yokoyama O: ["Pathophysiology and treatment of the overactive bladder"]. Hinyokika Kiyo; 2005 Sep;51(9):599-601
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ["Pathophysiology and treatment of the overactive bladder"].
  • The International Continence Society (ICS) recently derived a consensus symptomatic definition of overactive bladder (OAB) as urinary urgency, with or without urge incontinence, usually with frequency and nocturia.
  • It is not easy to confirm the etiology of OAB in patients with bladder outlet obstruction and neurological disease.
  • Urinary tract infection was accompanied by 84 ml of post-void residual.
  • [MeSH-major] Quality of Life. Urinary Incontinence / physiopathology. Urination Disorders / physiopathology
  • [MeSH-minor] Aged. Female. Humans. Male. Urinary Bladder, Neurogenic / physiopathology. Urinary Incontinence, Stress / physiopathology. Urinary Tract Infections / complications


13. Cohen BL, Caruso DJ, Kanagarajah P, Gousse AE: Predictors of response to intradetrusor botulinum toxin-A injections in patients with idiopathic overactive bladder. Adv Urol; 2009;:328364
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of response to intradetrusor botulinum toxin-A injections in patients with idiopathic overactive bladder.
  • OBJECTIVES: To evaluate whether there are any demographic or urodynamic differences in patients with idiopathic overactive bladder (I-OAB) that respond and do not respond to intradetrusor injections of botulinum toxin-A (BTX-A).
  • RESULTS: In patients with overactive bladder without incontinence (OAB-Dry), there were no variables that could be used to predict response to BTX-A.
  • On univariate analysis, younger patients with overactive bladder with incontinence (OAB-Wet) were more likely to respond to BTX-A than older patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2008 Mar;71(3):455-9 [18342186.001]
  • [Cites] J Urol. 2007 Mar;177(3):1006-10; discussion 1010 [17296397.001]
  • [Cites] Eur Urol. 2006 Nov;50(5):1058-64 [16517054.001]
  • [Cites] Neurourol Urodyn. 2000;19(5):553-64 [11002298.001]
  • [Cites] J Urol. 2006 Jun;175(6):2178-80; discussion 2180-1 [16697833.001]
  • [Cites] Neurourol Urodyn. 2002;21(2):167-78 [11857671.001]
  • [Cites] BJU Int. 2001 Jun;87(9):760-6 [11412210.001]
  • [Cites] J Urol. 2006 Jul;176(1):177-85 [16753396.001]
  • (PMID = 19746201.001).
  • [ISSN] 1687-6369
  • [Journal-full-title] Advances in urology
  • [ISO-abbreviation] Adv Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2739422
  •  go-up   go-down


14. Fritz N, Morel JL, Jeyakumar LH, Fleischer S, Allen PD, Mironneau J, Macrez N: RyR1-specific requirement for depolarization-induced Ca2+ sparks in urinary bladder smooth muscle. J Cell Sci; 2007 Nov 1;120(Pt 21):3784-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RyR1-specific requirement for depolarization-induced Ca2+ sparks in urinary bladder smooth muscle.
  • Here, we used Ryr1-null mice to investigate the role of this isoform in Ca(2+) signaling in urinary bladder smooth muscle.
  • Moreover, treatment with rapamycin, which uncouples FKBPs from RyR, led to an increase of RyR-dependent Ca(2+) signaling in wild-type urinary bladder myocytes but not in Ryr1(-/-) myocytes.
  • In conclusion, although decreased amounts of FKBP increase Ca(2+) signals in Ryr1(-/-) urinary bladder myocytes the depolarization-induced Ca(2+) sparks are specifically lost, demonstrating that RyR1 is required for depolarization-induced Ca(2+) sparks and suggesting that the intracellular localization of RyR1 fine-tunes Ca(2+) signals in smooth muscle.
  • [MeSH-major] Calcium / metabolism. Calcium Signaling / physiology. Muscle, Smooth / metabolism. Myocytes, Smooth Muscle / metabolism. Ryanodine Receptor Calcium Release Channel / metabolism. Urinary Bladder / anatomy & histology

  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. CAFFEINE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925380.001).
  • [ISSN] 0021-9533
  • [Journal-full-title] Journal of cell science
  • [ISO-abbreviation] J. Cell. Sci.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / 1P01 AR17605
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Central Nervous System Stimulants; 0 / Ryanodine Receptor Calcium Release Channel; 3G6A5W338E / Caffeine; EC 5.2.1.- / Tacrolimus Binding Protein 1A; SY7Q814VUP / Calcium; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


15. Kitsukawa S, Aoyagi T, Noda K, Ito T, Yamamoto Y, Hosoda S, Otsuru N, Matsumoto T: Quantitative analysis of survivin mRNA expression in bladder transitional cell carcinomas. Hinyokika Kiyo; 2008 Feb;54(2):101-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of survivin mRNA expression in bladder transitional cell carcinomas.
  • We assessed the expression levels of survivin mRNA in bladder transitional cell carcinoma (TCC) to provide additional information regarding its malignant potential.
  • The real-time PCR method was used to detect the survivin mRNA level for 21 bladder tumor specimens, and for urinary exfoliated cells from 12 newly diagnosed bladder tumor patients.
  • All bladder tumor specimens and 7 of 12 voided urine specimens expressed survivin mRNA.
  • In tumor specimens, high grade, high stage tumors had the tendency to express more survivin mRNA.
  • Of 12 superficial bladder tumor patients who had transurethral resection of bladder tumor (TURB), 3 showed high survivin mRNA expression and intravesical recurrence after the surgery.
  • However, for the patients who had total cystectomy due to invasive tumor, no relations were observed between the survivin mRNA expression level and development of local recurrence and/or distant metastasis.
  • [MeSH-major] Carcinoma, Transitional Cell / chemistry. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis. Urinary Bladder Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323166.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


16. Mazo EB, Gazhonova VE, Chepurov DA: [Three-dimentional echography in diagnosis and staging of urinary bladder cancer]. Urologiia; 2005 May-Jun;(3):6-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three-dimentional echography in diagnosis and staging of urinary bladder cancer].
  • The role of USI and three-dimentional volumetric reconstruction was studied in diagnosis of urinary bladder cancer diagnosis.
  • Examination included renal USI of the kidneys, urinary bladder, prostate, echoureterography, cystoscopy, CT, MRT.
  • The number of the tumors, volume, area, invasion were studied in 3D mode.
  • US angiography assessed resistance index and tumor vascularization by degrees 0-3.
  • 2D USI technique proved effective in detection of urinary bladder cancer at stage T1 in 66%, 3D in 100.
  • Overall informative value of 2D in detection of urinary bladder cancer was 81%, three-dimentional echography--96%.
  • USI proved effective in diagnosis and staging of urinary bladder cancer.
  • Use of 3D ultrasonic angiography facilitates the choice of more effective surgical policy in the treatment of urinary bladder cancer patients.
  • [MeSH-major] Imaging, Three-Dimensional. Neovascularization, Pathologic / ultrasonography. Ultrasonography / methods. Urinary Bladder Neoplasms / ultrasonography
  • [MeSH-minor] Aged. Cystoscopy. Female. Humans. Kidney / ultrasonography. Male. Middle Aged. Neoplasm Staging. Prostate / ultrasonography. Urinary Bladder / pathology. Urinary Bladder / ultrasonography

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100784.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


17. Boccardo F, Palmeri L: Adjuvant chemotherapy of bladder cancer. Ann Oncol; 2006 May;17 Suppl 5:v129-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy of bladder cancer.
  • BACKGROUND: Bladder cancer is one of the most common genitourinary cancer.
  • PATIENTS AND METHODS: We performed a review of clinical trials and metanalysis of adjuvant treatment for muscle-invasive bladder cancer.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807440.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 23
  •  go-up   go-down


18. Shimada O, Wu X, Jin X, Nouh MA, Fiscella M, Albert V, Matsuda T, Kakehi Y: Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells. Urology; 2007 Feb;69(2):395-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
  • OBJECTIVES: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in a variety of tumor cells through two of its receptors: TRAIL-R1 and TRAIL-R2.
  • In this study, we investigated the susceptibility of human prostate cancer and bladder cancer cells to HGS-ETR2, a human monoclonal agonistic antibody specific for TRAIL-R2.
  • METHODS: The cell surface expression of TRAIL-R1 and TRAIL-R2 on prostate cancer and bladder cancer cells was determined using flow cytometry.
  • RESULTS: HGS-ETR2 effectively induced apoptotic cell death in DU145, PC3, and LNCaP human prostate cancer cells and J82 and T24 human bladder cancer cells.
  • The increased effectiveness of HGS-ETR2 for inducing cell death might have been affected by differences in the cell surface expression of the two TRAIL receptors, in that TRAIL-R2, but not TRAIL-R1, was frequently expressed in the prostate cancer and bladder cancer cells.
  • Caspase-3, -6, and -9 were also significantly activated with HGS-ETR2-induced apoptosis in the bladder cancer cells.
  • CONCLUSIONS: These findings suggest the potential utility of TRAIL-R2 antibody as a novel therapeutic agent against prostate cancer and bladder cancer.
  • [MeSH-major] Apoptosis / drug effects. Receptors, TNF-Related Apoptosis-Inducing Ligand / pharmacology. Receptors, Tumor Necrosis Factor, Type II / pharmacology
  • [MeSH-minor] Apoptosis Regulatory Proteins / drug effects. Apoptosis Regulatory Proteins / metabolism. Caspases / metabolism. Cell Line, Tumor / drug effects. Flow Cytometry. Humans. Male. Probability. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Sensitivity and Specificity. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320696.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor, Type II; EC 3.4.22.- / Caspases
  •  go-up   go-down


19. Sugaya K, Nishijima S, Tasaki S, Kadekawa K, Miyazato M, Ogawa Y: Mechanisms by which a phytotherapeutic drug influences bladder activity in rats. J Urol; 2008 Feb;179(2):770-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms by which a phytotherapeutic drug influences bladder activity in rats.
  • PURPOSE: We investigated the mechanisms by which Eviprostat, a phytotherapeutic drug for benign prostatic hyperplasia, influences bladder activity in rats.
  • After 2 weeks 14 rats (7 rats per group) underwent continuous cystometry with physiological saline or 0.1% acetic acid solution and bladder activity was recorded.
  • In the remaining 14 rats (7 per group) 0.1% acetic acid solution was infused into the bladder and urinary adenosine triphosphate was measured before and after stimulation.
  • RESULTS: During cystometry with acetic acid the interval between bladder contractions was shorter and maximum bladder contraction pressure was higher in the control group compared with results obtained using physiological saline but such differences were not seen in the Eviprostat group.
  • Urinary adenosine triphosphate was higher in the 2 groups than before stimulation but the increase was smaller in the Eviprostat group than in the control group.
  • CONCLUSIONS: These results suggest that Eviprostat acts to maintain low catecholamine and also inhibit pathological bladder activity by decreasing adenosine triphosphate release from the bladder.
  • [MeSH-major] Ethamsylate / pharmacology. Phytotherapy. Plant Extracts / pharmacology. Urinary Bladder / drug effects

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18082195.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Plant Extracts; 24YL531VOH / Ethamsylate; 59738-67-9 / eviprostat; 8L70Q75FXE / Adenosine Triphosphate
  •  go-up   go-down


20. Suleyman E, Yekeler E, Dursun M, Zorba UO, Tunc M, Tunaci A, Acunas B: Bladder tumors: virtual MR cystoscopy. Abdom Imaging; 2006 Jul-Aug;31(4):483-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder tumors: virtual MR cystoscopy.
  • Virtual cystoscopy is a promising new technique based on computer-simulated rendering of the inner surface of the urinary bladder using volumetric magnetic resonance (MR) imaging data, thus enabling maneuvers that normally are not possible with conventional cystoscopy.
  • The recent improvement in MR scanners has significantly facilitated virtual cystoscopic evaluation of the urinary bladder lumen by MR imaging.
  • Volumetric data associated with powerful postprocessing procedures allow imaging of the inner urinary bladder surface with excellent detail.
  • [MeSH-major] Cystoscopy / methods. Magnetic Resonance Imaging / methods. Urinary Bladder Neoplasms / diagnosis. User-Computer Interface

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16568363.001).
  • [ISSN] 0942-8925
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Number-of-references] 26
  •  go-up   go-down


21. Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol; 2009 Sep;56(3):534-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
  • BACKGROUND: Some men receiving alpha-blocker therapy for lower urinary tract symptoms report persistent storage symptoms suggestive of overactive bladder (OAB).
  • DESIGN, SETTING, AND PARTICIPANTS: This double-blind trial included men aged > or = 40 yr with frequency, urgency, and at least moderate problems reported on the Patient Perception of Bladder Condition (PPBC), despite being on a stable dose of alpha-blocker for > or = 1 mo.
  • MEASUREMENTS: At baseline and week 12, subjects completed the PPBC, International Prostate Symptom Score (IPSS), Overactive Bladder Questionnaire (OAB-q), and 5-d bladder diaries using the five-point Urinary Sensation Scale (USS).
  • Acute urinary retention requiring catheterization occurred in < 1% of either group.
  • There were no clinically meaningful changes in postvoid residual volume or maximum urinary flow rate.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Benzhydryl Compounds / therapeutic use. Cresols / therapeutic use. Muscarinic Antagonists / therapeutic use. Phenylpropanolamine / therapeutic use. Urinary Bladder, Overactive / drug therapy

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PHENYLPROPANOLAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2009 Sep;56(3):542-3 [19070420.001]
  • [CommentIn] Eur Urol. 2009 Sep;56(3):542 [19070419.001]
  • (PMID = 19070418.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00282932
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Benzhydryl Compounds; 0 / Cresols; 0 / Muscarinic Antagonists; 33RU150WUN / Phenylpropanolamine; 5T619TQR3R / Tolterodine Tartrate
  •  go-up   go-down


22. Moyano Calvo JL, Maqueda Marín Mde L, Dávalos Casanova G, Sánchez de la Vega J, Giraldez Puig J, Huesa Ramírez FI, Maestro Durán JL, Ramírez Mendoza A, Morales López A: [Bladder leiomyoma in a 17-year-old male patient]. Arch Esp Urol; 2005 Nov;58(9):954-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder leiomyoma in a 17-year-old male patient].
  • [Transliterated title] Leiomioma vesical en paciente varón de diecisiete años.
  • OBJECTIVES: Bladder leiomyoma is a rare tumor, its frequency being estimated below 1%.
  • METHODS: We report the case of a 17-year-old mole patient presenting with hematuria and lower urinary tract irritative symptoms whose work up discovered two small bladder tumors.
  • RESULTS: After TUR of the lesions the diagnosis of bladder leiomyoma was established; no recurrences have appeared on follow-up.
  • CONCLUSIONS: Bladder leiomyoma is a benign tumor, therefore surgery should be the most conservative.
  • [MeSH-major] Leiomyoma / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430045.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 8
  •  go-up   go-down


23. Radziszewski P, Majewski M, Baranowski W, Czaplicki M, Bossowska A, Dobroński P, Borkowski A: Re-innervation pattern of the 'neovagina' created from the bladder flap in patients with Mayer-Rokitanski-Kistner-Hauser syndrome: an immunochemical study. Gynecol Endocrinol; 2009 Jun;25(6):362-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re-innervation pattern of the 'neovagina' created from the bladder flap in patients with Mayer-Rokitanski-Kistner-Hauser syndrome: an immunochemical study.
  • Therefore, we decided to elucidate the pattern of sensory re-innervation of the bladder flap used for the surgery.
  • METHODS: Biopsies were taken from vaginal vestibule and urinary bladder during the CVP and 1 year later in four patients with MRKHS.
  • This was similar to the pattern observed in the urinary bladder.
  • CONCLUSIONS: Our findings demonstrate considerable nervous system plasticity in the bladder flap.
  • Distribution of presumably sensory CGRP and PACAP immunoreactive nerve fibers was similar to the pattern observed within the intact bladder wall, and VIP or GAL immunoreactive nerve fibers (vasomotor functions) were distributed in a manner similar to that observed in the intact vaginal wall.
  • [MeSH-major] Surgically-Created Structures / innervation. Urinary Bladder / surgery. Vagina / innervation. Vagina / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479597.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neuropeptides
  •  go-up   go-down


24. Randi G, Pelucchi C, Negri E, Talamini R, Galeone C, Franceschi S, La Vecchia C: Family history of urogenital cancers in patients with bladder, renal cell and prostate cancers. Int J Cancer; 2007 Dec 15;121(12):2748-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family history of urogenital cancers in patients with bladder, renal cell and prostate cancers.
  • To evaluate the risks of bladder, prostate and renal cell neoplasms for family history of urogenital cancers in first-degree relatives, we analysed data from a case-control study conducted in northern Italy between 1985 and 1992 and including a total of 1,356 incident, histologically confirmed cancer cases: 727 bladder, 348 renal cell and 281 prostate cancer cases.
  • ORs of urogenital cancers for subjects with at least 1 first-degree relative with cancer at the same site were 6.1 [95% confidence interval (CI), 2.3-16.6] for bladder, 2.0 (95% CI: 0.6-6.2) for renal cell and 2.0 (95% CI: 0.9-4.1) for prostate cancer.
  • [MeSH-major] Carcinoma, Renal Cell / epidemiology. Kidney Neoplasms / epidemiology. Prostatic Neoplasms / epidemiology. Urinary Bladder Neoplasms / epidemiology. Urogenital Neoplasms / epidemiology. Urogenital Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17724720.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Andrew AS, Gui J, Sanderson AC, Mason RA, Morlock EV, Schned AR, Kelsey KT, Marsit CJ, Moore JH, Karagas MR: Bladder cancer SNP panel predicts susceptibility and survival. Hum Genet; 2009 Jun;125(5-6):527-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer SNP panel predicts susceptibility and survival.
  • Bladder cancer is the fourth most common malignancy in men and the eighth most common in women in western countries.
  • Using a population-based study with 832 bladder cancer cases and 1,191 controls, we assessed genetic variation in relation to cancer susceptibility or survival.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 2002 Sep 30;506-507:29-40 [12351142.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4519-24 [12154064.001]
  • [Cites] Genet Epidemiol. 2003 Feb;24(2):150-7 [12548676.001]
  • [Cites] Gut. 2003 Jul;52(7):1017-24 [12801960.001]
  • [Cites] Cancer Lett. 2004 Aug 10;211(2):199-207 [15219943.001]
  • [Cites] Int J Cancer. 1985 Jun 15;35(6):703-6 [4008097.001]
  • [Cites] J Urol. 1998 Apr;159(4):1348-53 [9507882.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):901-4 [9625842.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1603-8 [9676833.001]
  • [Cites] Environ Health Perspect. 1998 Aug;106 Suppl 4:1047-50 [9703491.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1631-9 [15547700.001]
  • [Cites] JAMA. 2004 Dec 22;292(24):3026-9 [15613673.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1368-73 [15802297.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):3109-16 [16080574.001]
  • [Cites] Lancet. 2005 Aug 20-26;366(9486):649-59 [16112301.001]
  • [Cites] Int J Hyg Environ Health. 2005;208(5):321-7 [16217917.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2569-78 [16284380.001]
  • [Cites] Urology. 2005 Dec;66(6 Suppl 1):4-34 [16399414.001]
  • [Cites] Am J Hum Genet. 2006 Mar;78(3):464-79 [16465622.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):536-42 [16537713.001]
  • [Cites] J Hum Genet. 2006;51(3):196-203 [16429233.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2113-8 [16288216.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):1030-7 [16311243.001]
  • [Cites] Oncology. 2006;70(3):231-7 [16837776.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):606-9 [17372259.001]
  • [Cites] Virchows Arch. 2007 Apr;450(4):419-24 [17333265.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2452-8 [17311259.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2526-32 [17438114.001]
  • [Cites] Acta Oncol. 2007;46(1):31-41 [17438703.001]
  • [Cites] Anticancer Res. 2007 Mar-Apr;27(2):1025-30 [17465238.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Jul 1;176(1):48-53 [17574963.001]
  • [Cites] World J Urol. 2007 Jun;25(3):285-95 [17530260.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1230-42 [17496311.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1595-600 [17684133.001]
  • [Cites] Curr Opin Urol. 2007 Sep;17(5):341-6 [17762628.001]
  • [Cites] Int J Oncol. 2007 Oct;31(4):793-802 [17786310.001]
  • [Cites] J Urol. 2007 Oct;178(4 Pt 1):1196-200; discussion 1200 [17698105.001]
  • [Cites] Br J Cancer. 2007 Sep 17;97(6):832-6 [17848914.001]
  • [Cites] Neoplasia. 2007 Sep;9(9):707-15 [17898866.001]
  • [Cites] Nat Struct Mol Biol. 2007 Oct;14(10):912-20 [17906639.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1507-13 [17683075.001]
  • [Cites] Neoplasma. 2007;54(6):484-9 [17949231.001]
  • [Cites] Cell Mol Life Sci. 2008 Feb;65(3):359-75 [17965833.001]
  • [Cites] FEBS J. 2008 Mar;275(6):1089-102 [18279392.001]
  • [Cites] Hum Mol Genet. 2008 May 15;17(10):1457-64 [18250100.001]
  • [Cites] Lung Cancer. 2008 Jul;61(1):21-9 [18221821.001]
  • [Cites] Gut. 2008 Aug;57(8):1090-6 [18308828.001]
  • [Cites] Virchows Arch. 2008 Aug;453(2):165-70 [18648853.001]
  • [Cites] J Histochem Cytochem. 2008 Sep;56(9):853-61 [18574251.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5635-9 [18765558.001]
  • [Cites] Nature. 2008 Sep 4;455(7209):119-23 [18615013.001]
  • [Cites] Carcinogenesis. 2008 Oct;29(10):1955-62 [18632753.001]
  • [Cites] Bioinformatics. 2008 Dec 1;24(23):2784-5 [18854360.001]
  • [Cites] Gut. 2009 May;58(5):661-7 [18523027.001]
  • [Cites] J Biochem. 2000 Mar;127(3):475-83 [10731720.001]
  • [Cites] Int J Oncol. 2000 Aug;17(2):317-22 [10891541.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):138-47 [11404819.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):568-75 [11506498.001]
  • [Cites] Eur Urol. 2001 Nov;40(5):509-14 [11752857.001]
  • [Cites] Int J Urol. 2002 Jan;9(1):29-35 [11972647.001]
  • [Cites] Urol Res. 2002 Oct;30(5):282-8 [12389115.001]
  • (PMID = 19252927.001).
  • [ISSN] 1432-1203
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] ENG
  • [Grant] United States / NLM NIH HHS / LM / LM009012; United States / NCI NIH HHS / CA / R01 CA057494; United States / NCI NIH HHS / CA / R01 CA057494-14; United States / NIEHS NIH HHS / ES / ES00002; United States / NCI NIH HHS / CA / CA82354; United States / NCI NIH HHS / CA / CA121382; United States / NIEHS NIH HHS / ES / P30 ES000002; United States / NIEHS NIH HHS / ES / P42 ES007373; United States / NCRR NIH HHS / RR / P20 RR018787; United States / NCI NIH HHS / CA / R03 CA099500; United States / NCI NIH HHS / CA / R01 CA078609; United States / NIEHS NIH HHS / ES / ES007373; United States / NCI NIH HHS / CA / CA102327; United States / NCI NIH HHS / CA / CA057494-14; United States / NCI NIH HHS / CA / R03 CA121382; United States / NCI NIH HHS / CA / CA078609; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCRR NIH HHS / RR / RR018787; United States / NCI NIH HHS / CA / CA57494; United States / NIEHS NIH HHS / ES / P42 ES005947; United States / NCI NIH HHS / CA / K07 CA102327; United States / NLM NIH HHS / LM / R01 LM009012; United States / NCI NIH HHS / CA / CA099500; United States / NIEHS NIH HHS / ES / P42 ES05947; United States / NCI NIH HHS / CA / R01 CA082354; United States / NCRR NIH HHS / RR / P20 RR018728
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS123213; NLM/ PMC2763504
  •  go-up   go-down


26. Hughes M, Morrison A, Jackson R: Primary bladder lymphoma: management and outcome of 12 patients with a review of the literature. Leuk Lymphoma; 2005 Jun;46(6):873-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bladder lymphoma: management and outcome of 12 patients with a review of the literature.
  • Primary bladder non-Hodgkin's lymphoma (NHL) is rare.
  • Using the Scotland and Newcastle lymphoma group database, 12 patients with primary bladder lymphoma were identified between 1980 and 2001, the largest single group of patients available to date.
  • A review of 88 additional cases in the literature support the findings that primary bladder lymphoma is associated with a good prognosis.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019532.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Damaraju S, Damaraju VL, Mowles D, Sawyer MB, Damaraju S, Cass CE: Cytotoxic activity of gemcitabine in cultured cell lines derived from histologically different types of bladder cancer: role of thymidine kinase 2. Biochem Pharmacol; 2010 Jan 1;79(1):21-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic activity of gemcitabine in cultured cell lines derived from histologically different types of bladder cancer: role of thymidine kinase 2.
  • World wide incidence of bladder cancer is rising with nearly 13,760 deaths attributed to bladder cancer in 2007 in the USA.
  • Tumor types of the urothelium include transitional cell carcinomas, squamous cell carcinomas, and adenocarcinomas.
  • This study was undertaken to determine gemcitabine's efficacy against bladder cancer cell lines of different origins (HTB2, a papilloma; HTB3, a squamous cell carcinoma; and HTB4, a transitional cell carcinoma).
  • Roles of nucleoside transporters and key enzymes in gemcitabine pharmacology were examined on the premise that cells originating from different types of bladder cancer exhibit different levels and/or types of nucleoside transporters and enzymes and thus may respond differently to gemcitabine.
  • Elevated TK expression in squamous cell carcinomas warrants further study and offers new insights into rational treatment strategies based on bladder cancer phenotype.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Thymidine Kinase / physiology. Urinary Bladder Neoplasms / enzymology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Dose-Response Relationship, Drug. Humans. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19660438.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.7.1.- / thymidine kinase 2; EC 2.7.1.21 / Thymidine Kinase
  •  go-up   go-down


28. Lin HC, Wu WJ, Ke HL, Huang CH: Bladder leiomyoma presenting as voiding dysfunction: a case report. Kaohsiung J Med Sci; 2006 Mar;22(3):154-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder leiomyoma presenting as voiding dysfunction: a case report.
  • Mesenchymal tumors of the urinary bladder are rare, and the majority of them are malignant.
  • We report a case of leiomyoma of the urinary bladder presenting with symptoms of voiding dysfunction.
  • We performed surgical resection of the leiomyoma and repair of the bladder.
  • Small capacity of the bladder with right vesicoureteral reflux was noted in outpatient department follow-up.
  • [MeSH-major] Leiomyoma / complications. Urinary Bladder Neoplasms / complications. Urination Disorders / etiology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16602281.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


29. Vermandel A, de Wachter S, Wyndaele JJ: Refractory monosymptomatic nocturnal enuresis: a combined stepwise approach in childhood and follow-up into adolescence, with attention to the clinical value of normalizing bladder capacity. BJU Int; 2005 Sep;96(4):629-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractory monosymptomatic nocturnal enuresis: a combined stepwise approach in childhood and follow-up into adolescence, with attention to the clinical value of normalizing bladder capacity.
  • OBJECTIVE: To assess the importance of normalizing bladder capacity to the age-expected capacity in children with refractory monosymptomatic nocturnal enuresis (MNE), and to evaluate the long-term results when these children grow into adolescence.
  • Data were obtained on their enuretic state, night-time voiding behaviour and bladder capacity, from a questionnaire and a voiding chart.
  • RESULTS: Before starting treatment, all patients had a bladder capacity that was too small for their age.
  • Although the bladder capacity was increased to the age-expected capacity in 26 (76%), most woke at night to void.
  • Only those who were dry after primary treatment and remained dry had a normal age-expected increase in bladder capacity.
  • For all others there was a decrease in age-related bladder capacity.
  • CONCLUSIONS: In patients with refractory MNE, a combined stepwise approach improves and may even eliminate enuresis, but normal night-time bladder behaviour in adolescence and adulthood is only achieved in some.
  • [MeSH-major] Enuresis / pathology. Enuresis / therapy. Physical Therapy Modalities. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bedwetting.
  • Hazardous Substances Data Bank. OXYBUTYNIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16104923.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholinergic Antagonists; 0 / Mandelic Acids; K9P6MC7092 / oxybutynin
  •  go-up   go-down


30. Cohen SM, Ohnishi T, Clark NM, He J, Arnold LL: Investigations of rodent urinary bladder carcinogens: collection, processing, and evaluation of urine and bladders. Toxicol Pathol; 2007 Apr;35(3):337-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigations of rodent urinary bladder carcinogens: collection, processing, and evaluation of urine and bladders.
  • Examination of the urine and the bladder epithelium are essential to the investigation of mechanisms of urinary bladder carcinogens in rodents.
  • However, urine and bladder tissue specimens must be collected and processed properly if accurate data are to be derived.
  • The optimum specimen for analysis of urinary constituents is fresh void urine collected from nonfasting animals.
  • Many of the normal urinary constituents can influence the mode of action of bladder carcinogens, especially for non-genotoxic agents.
  • Light microscopy is routinely used to examine the bladder epithelium.
  • The urinary bladder must be handled gently and inflated with fixative in situ before the animal dies to avoid artifactual autolytic damage to the bladder epithelium that is visible by SEM and may be mistaken for treatment-related changes.
  • The purpose of this paper is to provide information for the proper collection and examination of urine and the urinary bladder.
  • [MeSH-major] Carcinogens / toxicity. Specimen Handling / methods. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology. Urine


31. Yadav BS, Ghoshal S, Sharma SC: Outcome following radical cystectomy and bladder-preservation therapy in patients with invasive carcinoma of urinary bladder. Indian J Urol; 2008 Jan;24(1):48-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome following radical cystectomy and bladder-preservation therapy in patients with invasive carcinoma of urinary bladder.
  • BACKGROUND: Invasive bladder cancer is a lethal disease with a 50% cancer-related mortality even in the best healthcare systems.
  • PURPOSE: To audit the outcome of multi-modality treatment and compare this with the existing literature in order to set future priorities and re-audit in patients with invasive carcinoma of urinary bladder.
  • MATERIALS AND METHODS: Between January 2001 and December 2004, 97 patients with invasive carcinoma of urinary bladder were analyzed.
  • Bladder was preserved in 61% of patients who received chemoradiation as compared to 42% in patients treated with radical radiation.
  • CONCLUSION: In patients with invasive bladder cancer, combined modality in the form of radical cystectomy followed by radiation give best local control.
  • Radiation alone is not effective to control muscle-invasive local disease; however, Chemoradiation is an effective alternative to radical cystectomy to preserve bladder function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Radiat Oncol. 2005 Jan;15(1):19-27 [15662603.001]
  • [Cites] Semin Radiat Oncol. 2005 Jan;15(1):28-35 [15662604.001]
  • [Cites] Radiother Oncol. 1998 Nov;49(2):149-55 [10052880.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):121-7 [9422567.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1022-9 [9060542.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):119-26 [8558186.001]
  • [Cites] Radiother Oncol. 1995 Sep;36(3):183-8 [8532904.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):247-54 [7836076.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Sep 30;30(2):261-6 [7928455.001]
  • [Cites] N Engl J Med. 1993 Nov 4;329(19):1377-82 [8413433.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):783-90 [8478228.001]
  • [Cites] Radiother Oncol. 1991 Oct;22(2):111-7 [1957001.001]
  • [Cites] Lancet Oncol. 2003 Aug;4(8):489-97 [12901963.001]
  • [Cites] J Urol. 2003 Jul;170(1):35-41 [12796639.001]
  • [Cites] Cancer. 2003 Apr 15;97(8 Suppl):2115-9 [12673704.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):690-6 [12586807.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1239-45 [10613319.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1371-9 [16580495.001]
  • (PMID = 19468359.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2684249
  • [Keywords] NOTNLM ; Carcinoma / chemoradiation / radiotherapy / urinary bladder
  •  go-up   go-down


32. Yamada S, Takeuchi C, Oyunzul L, Ito Y: Bladder angiotensin-II receptors: characterization and alteration in bladder outlet obstruction. Eur Urol; 2009 Feb;55(2):482-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder angiotensin-II receptors: characterization and alteration in bladder outlet obstruction.
  • BACKGROUND: It is assumed that angiotensin II (AngII) is significantly implicated in the pathogenesis of urinary dysfunction because of bladder outlet obstruction (BOO).
  • OBJECTIVE: The current study was undertaken to characterize AngII receptors in the rat bladder in relation to BOO.
  • MEASUREMENTS: Bladder AngII receptors were measured by a sensitive binding assay using a specific antagonist radioligand, [(125)I]-Sar(1)-Ile(8)-AngII, in bladder outlet-obstructed rats with and without repeated oral administration of telmisartan.
  • RESULTS AND LIMITATIONS: [(125)I]-Sar(1)-Ile(8)-AngII bound specifically to the rat bladder homogenates with high affinity.
  • These findings revealed the significant existence of pharmacologically relevant AngII (AT(1)) receptors in the bladder with relatively high density.
  • Oral administration of telmisartan in rats has been shown to bind to the bladder AngII receptors.
  • Bladder weight was about three times greater in bladder outlet-obstructed rats than in sham rats.
  • Maximal number of binding sites (B(max)) for [(125)I]-Sar(1)-Ile(8)-AngII binding in the bladder was significantly (48%) decreased in the bladder-outlet rats when compared with sham rats, suggesting the down regulation of pharmacologically relevant AngII receptor sites.
  • Notably, repeated oral administration of telmisartan (3mg/kg/d, 14 d) in rats completely prevented the development of a BOO-induced decrease in B(max) for bladder [(125)I]-Sar(1)-Ile(8)-AngII binding.
  • Telmisartan treatment also effectively attenuated the increase in the bladder-wet weight caused by urinary outlet obstruction.
  • CONCLUSIONS: Bladder AngII may be at least partly associated with the pathogenesis of urinary dysfunction occurring subsequent to BOO through stimulation of the AT(1) receptor subtype.
  • [MeSH-major] Angiotensin II Type 1 Receptor Blockers / therapeutic use. Benzimidazoles / therapeutic use. Benzoates / therapeutic use. Urinary Bladder / physiopathology. Urinary Bladder Neck Obstruction / drug therapy. Urinary Bladder Neck Obstruction / physiopathology

  • Hazardous Substances Data Bank. TELMISARTAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2009 Feb;55(2):489-90 [18378066.001]
  • (PMID = 18378069.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Benzimidazoles; 0 / Benzoates; U5SYW473RQ / telmisartan
  •  go-up   go-down


33. Tamura K, Nakajima F, Izawa A: [A case of small cell carcinoma in a diverticulum of the bladder]. Nihon Hinyokika Gakkai Zasshi; 2007 Mar;98(3):573-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of small cell carcinoma in a diverticulum of the bladder].
  • We report a case of small cell carcinoma in a diverticulum of the bladder.
  • A 64-year-old Japanese man visited our hospital with the chief complaint of urinary retention.
  • Cystoscopy revealed a papillary tumor arising in a diverticulum on the right lateral wall of the bladder.
  • Partial cystectomy was performed under the diagnosis of bladder cancer in the diverticulum.
  • The histopathological diagnosis was a combination of small cell carcinoma and urothelial carcinoma, of which the former was dominant.
  • It is often difficult to detect tumors in the bladder diverticula and its early penetration is not rare because of the thin wall.
  • Therefore, the prognosis of the bladder cancer in the diverticulum is believed to be generally poor.
  • On the other hand, small cell carcinoma originating in the urinary bladder is also characterized by its extreme rareness and poor prognosis.
  • To our knowledge, this is the second case report of the small cell carcinoma arising in a diverticulum of the urinary bladder in the Japanese literature.
  • [MeSH-major] Carcinoma, Small Cell / etiology. Diverticulum / pathology. Urinary Bladder Diseases / pathology. Urinary Bladder Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419368.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


34. Kos MK, Bogataj M, Mrhar A: Heparin decreases permeability of pig urinary bladder wall preliminarily enhanced by chitosan. Drug Dev Ind Pharm; 2008 Feb;34(2):215-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heparin decreases permeability of pig urinary bladder wall preliminarily enhanced by chitosan.
  • Chitosan significantly increases the permeability of the isolated pig urinary bladder wall by causing urothelial desquamation, the extent of which depends also on the concentration of the polymer.
  • To gain additional insight into the mechanism by which chitosan acts an absorption enhancer into urinary bladder mucosa, we evaluated the influence of a polysaccharide heparin on the permeability of isolated pig urinary bladder wall preliminarily treated with chitosan.
  • In the permeability studies performed by the use of diffusion cells, transport of a model drug, pipemidic acid, into the isolated pig urinary bladder wall was determined.
  • When applied to the urinary bladder wall, whose permeability was preliminarily enhanced by 0.005% or 0.001% w/v chitosan, heparin decreased the permeation of pipemidic acid into the bladder wall to a level not significantly different from the intact tissue.
  • By application on the urothelium, damaged by chitosan, heparin is supposed to form a layer on the surface of the urothelium that prevents the transport of the model drug into the bladder wall.
  • In this way heparin probably restores the impermeability properties of the urinary bladder wall to a degree dependent on the urothelial damage.
  • [MeSH-major] Chitosan / pharmacology. Heparin / pharmacology. Urinary Bladder / metabolism

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302041.001).
  • [ISSN] 0363-9045
  • [Journal-full-title] Drug development and industrial pharmacy
  • [ISO-abbreviation] Drug Dev Ind Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9005-49-6 / Heparin; 9012-76-4 / Chitosan; LT12J5HVR8 / Pipemidic Acid
  •  go-up   go-down


35. Lemy A, Wissing KM, Rorive S, Zlotta A, Roumeguere T, Muniz Martinez MC, Decaestecker C, Salmon I, Abramowicz D, Vanherweghem JL, Nortier J: Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am J Kidney Dis; 2008 Mar;51(3):471-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up.
  • The risk of bladder urothelial carcinoma after kidney transplantation and its relationship to upper-tract urothelial carcinoma is not well defined.
  • OUTCOMES & MEASUREMENTS: The prevalence of upper urinary tract urothelial carcinoma was determined by collecting pathological results of specimens obtained by means of bilateral ureteronephrectomy.
  • We also established the cumulative incidence of bladder urothelial carcinoma in biopsies performed during prospective screening cystoscopies during a 15-year follow-up.
  • During follow-up, bladder urothelial carcinoma was diagnosed in 15 patients 68 to 169 months after cessation of aristolochic acid exposure (39.5%): 8 urothelial carcinoma in situ, 4 noninvasive low-grade papillary urothelial carcinoma, and 3 infiltrating urothelial carcinoma.
  • 12 of 17 patients (71%) with a history of upper-tract urothelial carcinoma developed bladder urothelial carcinoma during follow-up, whereas this occurred in only 3 of 21 patients (14%) without upper-tract urothelial carcinoma (P < 0.01).
  • CONCLUSIONS: Upper-tract and bladder urothelial carcinoma are dramatic complications in kidney transplant recipients with aristolochic acid nephropathy, confirming the carcinogenic properties of aristolochic acids.
  • We identified upper-tract urothelial carcinoma as a potent risk factor for the subsequent development of bladder urothelial carcinoma after kidney transplantation for aristolochic acid nephropathy.
  • [MeSH-major] Carcinogens. Drugs, Chinese Herbal / adverse effects. Kidney Failure, Chronic / chemically induced. Kidney Failure, Chronic / surgery. Kidney Transplantation. Urinary Bladder Neoplasms / chemically induced


36. Cortessis VK, Yuan JM, Van Den Berg D, Jiang X, Gago-Dominguez M, Stern MC, Castelao JE, Xiang YB, Gao YT, Pike MC, Conti DV: Risk of urinary bladder cancer is associated with 8q24 variant rs9642880[T] in multiple racial/ethnic groups: results from the Los Angeles-Shanghai case-control study. Cancer Epidemiol Biomarkers Prev; 2010 Dec;19(12):3150-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of urinary bladder cancer is associated with 8q24 variant rs9642880[T] in multiple racial/ethnic groups: results from the Los Angeles-Shanghai case-control study.
  • Recent genome-wide association studies of urinary bladder cancer report risk to be associated with the T allele of rs9642880 on 8q24 among individuals of European descent.
  • METHODS: We examined associations between bladder cancer risk and genotypes defined by rs9642880 and each of 8 additional 8q24 variants associated with risk of other cancers, in both high-risk non-Hispanic white and low-risk Chinese participants enrolled in a large population-based case-control study conducted in Los Angeles County and Shanghai.
  • RESULTS: We confirmed association of rs9642880 T with bladder cancer risk not only among non-Hispanic whites but also among Chinese participants [overall per-allele relative risk estimate 1.32 (95% CI, 1.16-1.50; P = 0.000024)].
  • Subgroup analyses suggested that effects of rs9642880 are largely confined to nonsmokers and former smokers, and may be particularly important in the etiology of noninvasive papillary tumors.
  • There was little indication that 8q24 SNPs associated with other cancer types--rs7008482, rs7000448, rs6983561, rs6983267, rs13281615, rs13254738, or rs10090154--are associated with bladder cancer risk.
  • CONCLUSIONS: Bladder cancer risk is associated specifically with variation in the discrete 8q24 region containing rs9642880.
  • Factors other than rs9642880 genotypes seem to underlie differences in bladder cancer risk between non-Hispanic whites and Chinese.
  • IMPACT: Characterization of functional consequences of genetic variation in the discrete region including rs9642880 is needed to understand biological basis of this bladder cancer-specific 8q24 association in these racial/ethnic groups characterized by both high and low risk of bladder cancer.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Nat Genet. 2007 May;39(5):638-44 [17401364.001]
  • [Cites] Nat Genet. 2007 May;39(5):645-9 [17401363.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):954-6 [17618282.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):989-94 [17618283.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):984-8 [17618284.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23):11128-32 [18056436.001]
  • [Cites] Genome Res. 2007 Dec;17(12):1717-22 [17978284.001]
  • [Cites] J Natl Cancer Inst. 2008 Jul 2;100(13):962-6 [18577746.001]
  • [Cites] Nat Genet. 2008 Nov;40(11):1307-12 [18794855.001]
  • [Cites] Cancer Biol Ther. 2007 Jul;6(7):1143-7 [17630503.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):882-4 [19561607.001]
  • [Cites] PLoS Genet. 2009 Aug;5(8):e1000597 [19680443.001]
  • [Cites] Nat Genet. 2009 Sep;41(9):991-5 [19648920.001]
  • [Cites] J Natl Cancer Inst. 1985 Feb;74(2):291-7 [3856043.001]
  • [Cites] J Natl Cancer Inst. 1994 May 4;86(9):712-6 [8158701.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Nat Clin Pract Urol. 2005 Oct;2(10):502-10 [16474624.001]
  • [Cites] Nat Genet. 2006 Jun;38(6):652-8 [16682969.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14068-73 [16945910.001]
  • [Cites] Nat Genet. 2007 May;39(5):631-7 [17401366.001]
  • (PMID = 21051319.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA086871; United States / NCI NIH HHS / CA / R01 CA114665; United States / NCI NIH HHS / CA / 1P01CA86871; United States / NCI NIH HHS / CA / 1R01CA114665
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS392436; NLM/ PMC3417222
  •  go-up   go-down


37. Michaud DS, Holick CN, Giovannucci E, Stampfer MJ: Meat intake and bladder cancer risk in 2 prospective cohort studies. Am J Clin Nutr; 2006 Nov;84(5):1177-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meat intake and bladder cancer risk in 2 prospective cohort studies.
  • BACKGROUND: Nitrosamines, which are known bladder carcinogens, or their precursors are found in certain meat items, and concentrations of these compounds are especially high in bacon.
  • Only 3 cohort studies, all with <100 case subjects, have examined the relation between meat intake and bladder cancer, and few studies have examined the relation of different meat types with bladder cancer.
  • OBJECTIVE: The aim was to examine the association between specific meat items and bladder cancer in 2 large prospective studies.
  • DESIGN: We analyzed data from 2 cohorts with up to 22 y of follow-up and 808 incident bladder cancer cases.
  • RESULTS: Men and women with a high intake of bacon (>/=5 servings/wk) had an elevated risk of bladder cancer compared with those who never ate bacon (multivariate RR = 1.59; 95% CI = 1.06, 2.37), although the overall association was not statistically significant (P for trend = 0.06).
  • CONCLUSIONS: In these 2 cohorts combined, frequent consumption of bacon was associated with an elevated risk of bladder cancer.
  • [MeSH-major] Food Habits. Meat Products / adverse effects. Nitrosamines / adverse effects. Urinary Bladder Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17093172.001).
  • [ISSN] 0002-9165
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA55075; United States / NCI NIH HHS / CA / CA87969
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosamines
  •  go-up   go-down


38. Wolpert BJ, Amr S, Ezzat S, Saleh D, Gouda I, Loay I, Hifnawy T, Mikhail NN, Abdel-Hamid M, Zhan M, Zheng YL, Squibb K, Abdel-Aziz MA, Zaghloul M, Khaled H, Loffredo CA: Estrogen exposure and bladder cancer risk in Egyptian women. Maturitas; 2010 Dec;67(4):353-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen exposure and bladder cancer risk in Egyptian women.
  • OBJECTIVE: To examine associations between reproductive history and urinary bladder cancer in Egyptian women.
  • This analysis focused on female cases with confirmed urothelial (UC) and squamous cell (SCC) carcinoma of the bladder.
  • Younger age at menopause (<45 y) and older age at first pregnancy (>18 y) were factors significantly associated with increased risk of bladder cancer, even after adjusting for schistosomiasis history and other covariates in the multivariable logistic model; adjusted odds ratio and 95% confidence intervals were 1.98 (1.41, 2.77) and 6.26 (3.46, 11.34), respectively.
  • On the other hand, multiple pregnancies or use of oral contraceptives were associated with decreased odds of having bladder cancer.
  • CONCLUSION: Our data suggest that early estrogen exposure, or the relative lack of it, plays a role in urinary bladder carcinoma development among Egyptian women.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Pregnancy.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1093-8 [17131327.001]
  • [Cites] Int J Cancer. 2006 Nov 15;119(10):2398-401 [16894568.001]
  • [Cites] Nat Clin Pract Urol. 2007 Apr;4(4):205-17 [17415353.001]
  • [Cites] Nicotine Tob Res. 2007 May;9(5):591-6 [17454715.001]
  • [Cites] Tumori. 2007 Jan-Feb;93(1):4-12 [17455864.001]
  • [Cites] World J Urol. 2007 Jun;25(3):285-95 [17530260.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7540-5 [17671226.001]
  • [Cites] Cancer Causes Control. 2008 May;19(4):421-9 [18188671.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):412-9 [18792102.001]
  • [Cites] Br J Cancer. 2000 Apr;82(7):1364-9 [10755416.001]
  • [Cites] Am J Trop Med Hyg. 2000 Sep-Oct;63(3-4):133-8 [11388504.001]
  • [Cites] Cancer Causes Control. 2002 Feb;13(1):83-90 [11899922.001]
  • [Cites] Prev Med. 2002 Aug;35(2):114-20 [12200095.001]
  • [Cites] Int J Cancer. 2003 Jun 20;105(3):408-12 [12704678.001]
  • [Cites] Obstet Gynecol. 2003 Sep;102(3):565-70 [12962944.001]
  • [Cites] Urol Oncol. 2004 Mar-Apr;22(2):86-92 [15082003.001]
  • [Cites] J Egypt Soc Parasitol. 2003 Dec;33(3 Suppl):1031-50 [15119469.001]
  • [Cites] J Natl Cancer Inst. 1990 Oct 17;82(20):1636-40 [2213906.001]
  • [Cites] Cancer Causes Control. 1992 Jan;3(1):57-62 [1536914.001]
  • [Cites] Ann Epidemiol. 1993 Jul;3(4):429-33 [8275221.001]
  • [Cites] Acta Oncol. 1997;36(6):631-6 [9408155.001]
  • [Cites] Br J Cancer. 1998 Apr;77(7):1186-9 [9569060.001]
  • [Cites] Clin Microbiol Rev. 1999 Jan;12(1):97-111 [9880476.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Am J Epidemiol. 2006 Feb 1;163(3):236-44 [16319290.001]
  • [Cites] Am J Epidemiol. 2007 Mar 15;165(6):660-6 [17204516.001]
  • (PMID = 20813471.001).
  • [ISSN] 1873-4111
  • [Journal-full-title] Maturitas
  • [ISO-abbreviation] Maturitas
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA115618; United States / NCI NIH HHS / CA / 5R01-CA115618-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contraceptives, Oral; 0 / Estrogens
  • [Other-IDs] NLM/ NIHMS234455; NLM/ PMC3433170
  •  go-up   go-down


39. de Oliveira Querne FA, da Silva DC, Padovani GP, Coelho Alves Brasil Lde C, Brandalise NA, D'Ancona CA: Bladder autoaugmentation in dogs: assessment of different laparoscopic methods. J Endourol; 2009 Apr;23(4):699-703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder autoaugmentation in dogs: assessment of different laparoscopic methods.
  • PURPOSE: Bladder autoaugmentation was described in 1989, and the effectiveness of this surgical technique in the management of neurogenic bladder dysfunctions is still debated.
  • The aim of this study was to assess laparoscopic bladder autoaugmentation in dogs, allowing future studies to be developed using a uniform surgical technique and the results to be compared.
  • Laparoscopic bladder autoaugmentation was then attempted either with or without the use of the intravesical silicone balloon.
  • CONCLUSIONS: Laparoscopic bladder autoaugmentation is feasible in the canine model with and without the intravesical silicone balloon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335147.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Hori J, Kato Y, Hou K, Saga Y, Hashimoto H, Kakizaki H: [A case report of urinary reconstruction by ileal neobladder performed 16 years after total cystectomy for bladder cancer]. Nihon Hinyokika Gakkai Zasshi; 2007 Jan;98(1):34-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of urinary reconstruction by ileal neobladder performed 16 years after total cystectomy for bladder cancer].
  • We report a 59-year old male patient who successfully underwent urinary reconstruction by ileal neobladder that was performed 16 years after total cystectomy and ureterocutaneostomy for bladder cancer.
  • Then urinary reconstruction was planned in 2005.
  • Long time insertion of nephrostomy catheter causes several complications, such as urinary tract infection and formation of urinary stones.
  • To preserve renal function and improve quality of life, every chance for urinary reconstruction should be sought in those patients who suffer from upper urinary tract catheter troubles.
  • [MeSH-major] Cystectomy. Urinary Bladder Neoplasms / surgery. Urinary Diversion / methods
  • [MeSH-minor] Humans. Male. Middle Aged. Quality of Life. Reconstructive Surgical Procedures / methods. Time Factors. Urinary Reservoirs, Continent

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302293.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


41. Berkowitz J, Carter HB, Gearhart JP: Prostate cancer in patients with the bladder exstrophy-epispadias complex: insights and outcomes. Urology; 2008 Jun;71(6):1064-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer in patients with the bladder exstrophy-epispadias complex: insights and outcomes.
  • OBJECTIVES: With modern reconstructive surgical techniques and better neonatal intensive care unit care, patients with the bladder exstrophy-epispadias complex are now living much longer than they did previously.
  • As these patients age, the men will begin to seek out adult urologists for common conditions such as benign prostatic hyperplasia and prostate cancer screening.
  • RESULTS: The patient underwent radical retropubic prostatectomy by an adult urologic oncologist assisted by a pediatric urologist with expertise in bladder exstrophy.
  • The patient later required cystectomy and ileal conduit for disease at the bladder neck, as well as external beam radiotherapy and androgen deprivation therapy.
  • Special considerations of the diagnosis, management, and treatment of prostate cancer in this patient population are discussed.
  • [MeSH-major] Bladder Exstrophy / complications. Epispadias / complications. Prostatic Neoplasms / complications


42. Bower WF, Wong EMC, Yeung CK: Development of a validated quality of life tool specific to children with bladder dysfunction. Neurourol Urodyn; 2006;25(3):221-227
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a validated quality of life tool specific to children with bladder dysfunction.
  • AIMS: To date there have not been any generic or continence-specific measurement tools that allow clinicians to investigate quality of life in children with bladder dysfunction.
  • The aim of this research was to create a cross-cultural tool to assess and measure the wider psychosocial impact of current and new interventions for bladder dysfunction in children.
  • CONCLUSIONS: A cross-cultural tool that quantifies the holistic effect of bladder dysfunction in children has been designed and tested for validity.
  • [MeSH-major] Quality of Life. Surveys and Questionnaires. Urinary Bladder Diseases / psychology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16496391.001).
  • [ISSN] 0733-2467
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


43. Bhanot A, Bhanot A: Laparoscopic repair in intraperitoneal rupture of urinary bladder in blunt trauma abdomen. Surg Laparosc Endosc Percutan Tech; 2007 Feb;17(1):58-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic repair in intraperitoneal rupture of urinary bladder in blunt trauma abdomen.
  • OBJECTIVE: Intraperitoneal rupture of urinary bladder is a common condition associated with pelvic fractures.
  • We performed total laparoscopic repair of an intraperitoneal rupture of bladder.
  • METHOD: A 25-year-old woman presented with fracture of both pubic rami and signs of bladder rupture after a road traffic accident.
  • Ruptured urinary bladder and other visceral injuries were sutured laparoscopically.
  • CONCLUSIONS: Laparoscopic repair of intraperitoneal rupture of urinary bladder is an effective and minimally invasive technique.
  • [MeSH-major] Fractures, Bone / complications. Pubic Bone / injuries. Urinary Bladder / injuries. Wounds, Nonpenetrating / surgery

  • MedlinePlus Health Information. consumer health - Fractures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318060.001).
  • [ISSN] 1530-4515
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Sezhian N, Rimal D, Lawrence K, Suresh G: Squamous cell carcinoma of the bladder following PTFE implantation. Urol Int; 2007;79(1):90-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the bladder following PTFE implantation.
  • Squamous cell carcinoma of the bladder in non-bilharzial bladder usually presents in the 7th decade and is more common in males than females.
  • An association between recurrent urinary tract infection (UTI) and long-term catheterisation with carcinoma of the bladder has been established with the pathogenesis thought to be due to chronic irritation and inflammation.
  • In our case the patient had been free from recurrent UTI for 15 years prior to developing carcinoma of the bladder.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Polytetrafluoroethylene / adverse effects. Urinary Bladder Neoplasms / etiology. Urinary Tract Infections / complications. Urinary Tract Infections / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Urinary Tract Infections.
  • Hazardous Substances Data Bank. TEFLON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17627177.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 9002-84-0 / Polytetrafluoroethylene
  •  go-up   go-down


45. Nikpour P, Mowla SJ, Jafarnejad SM, Fischer U, Schulz WA: Differential effects of Nucleostemin suppression on cell cycle arrest and apoptosis in the bladder cancer cell lines 5637 and SW1710. Cell Prolif; 2009 Dec;42(6):762-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential effects of Nucleostemin suppression on cell cycle arrest and apoptosis in the bladder cancer cell lines 5637 and SW1710.
  • In this study, we have investigated the role of NS in bladder cancer.
  • MATERIALS AND METHODS: Expression of NS was determined by quantitative reverse transcription-polymerase chain reaction in bladder carcinoma cell lines and in normal uro-epithelial cell cultures.
  • RESULTS: High NS expression was found in most bladder carcinoma cell lines and normal uro-epithelial cells.
  • CONCLUSION: Our data indicate that NS expression is necessary for cell proliferation and evasion of apoptosis in bladder cancer cells, independent of its effect on p53.
  • [MeSH-major] Apoptosis / genetics. Carrier Proteins / physiology. Cell Cycle / genetics. Nuclear Proteins / physiology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Down-Regulation. GTP-Binding Proteins. Gene Knockdown Techniques. Humans. Mutation, Missense. RNA Interference. Reverse Transcriptase Polymerase Chain Reaction


46. Niu ZB, Yang Y, Hou Y, Chen H, Liu X, Wang CL: Lymphangioma of bladder. Urology; 2010 Oct;76(4):955-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphangioma of bladder.
  • Lymphangioma in the bladder is extremely rare.
  • Ultrasonography, computed tomogram, and retrograde urethrography showed a mass that was in the wall of the bladder.
  • The tumor was red and found to be bulging into the bladder on the right lateral wall of the bladder by cystoscopy.
  • A partial cystectomy was performed and histology revealed a lymphangioma of the bladder.
  • This case, to the authors' knowledge, represents the third reported case of lymphangioma of bladder.Lymphangiomas are benign, soft-tissue tumors of lymphatic origin.
  • They rarely affect the urinary system and a location in the bladder is extremely rare.
  • Only 2 cases of lymphangioma of the bladder have been reported worldwide since 1983.
  • The present report describes a patient with a lymphangioma of the bladder and the imaging characteristics of the lesion are reported, including imagings of sonography, computed tomography, retrograde urethrography, and histologic examination.
  • [MeSH-major] Lymphangioma / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Lymphangioma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20494412.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


47. Alam S, Das Choudhary MK, Islam K: Leech in urinary bladder causing hematuria. J Pediatr Urol; 2008 Feb;4(1):70-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leech in urinary bladder causing hematuria.
  • OBJECTIVE: To estimate efficacy of normal saline in the management of hematuria caused by accidental entry of a leech per urethra into the urinary bladder.
  • In all cases, a leech had entered the urinary bladder through the urethra causing hematuria.
  • They were managed by infusing 50ml of normal saline into the urinary bladder through the catheter that was then clamped for 3h.
  • CONCLUSION: Catheterization and irrigation of the urinary bladder with normal saline is a relatively simple, safe and inexpensive method of removing the leech and controlling hematuria.
  • [MeSH-major] Foreign Bodies / surgery. Hematuria / etiology. Hematuria / therapy. Leeches. Sodium Chloride / administration & dosage. Sodium Chloride / therapeutic use. Therapeutic Irrigation / methods. Urinary Bladder
  • [MeSH-minor] Adolescent. Animals. Child. Humans. Male. Urinary Catheterization

  • MedlinePlus Health Information. consumer health - Foreign Bodies.
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18631896.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 451W47IQ8X / Sodium Chloride
  •  go-up   go-down


48. Chai X, van Herk M, van de Kamer JB, Remeijer P, Bex A, Betgen A, De Reijke TM, Hulshof MC, Pos FJ, Bel A: Behavior of lipiodol markers during image guided radiotherapy of bladder cancer. Int J Radiat Oncol Biol Phys; 2010 May 1;77(1):309-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Behavior of lipiodol markers during image guided radiotherapy of bladder cancer.
  • PURPOSE: To investigate the stability of a novel type of markers used in partial bladder tumor irradiation and tumor deformation as indicated by the markers.
  • MATERIALS AND METHODS: In 15 patients with solitary bladder cancer, lipiodol was injected in the bladder wall during flexible cystoscopy to identify the tumor.
  • Finally, to study tumor deformation, the relative movement of each marker pair was correlated with the relative bladder volume (RBV).
  • The intensity of spots in both CT and CBCT was significantly higher than the surrounding bladder tissue.
  • CONCLUSIONS: Lipiodol markers are a feasible method to track bladder tumor by using online CBCT.
  • Tumor deformation is observed, especially for tumors that cross the defined bladder zones.
  • [MeSH-major] Cone-Beam Computed Tomography / methods. Contrast Media. Iodized Oil. Urinary Bladder Neoplasms / radiography
  • [MeSH-minor] Aged. Aged, 80 and over. Cystoscopy. Feasibility Studies. Female. Humans. Male. Netherlands. Tomography, X-Ray Computed / methods. Tumor Burden. Uncertainty

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137863.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 8001-40-9 / Iodized Oil
  •  go-up   go-down


49. Dittrich R, Beckmann MW, Maake C, Oppelt PG, Mueller A, Mueller S, Hoffmann I, Naumann G, Koelbl H, Maltaris T: The extracorporeal perfusion of the female pig detrusor as an experimental model for the study of bladder contractility. Neurourol Urodyn; 2007;26(7):1024-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The extracorporeal perfusion of the female pig detrusor as an experimental model for the study of bladder contractility.
  • The intravesical pressure of the bladder as well as the intraarterial pressure of the vesical arteries were recorded before and after administration of carbachol.
  • Carbachol was able to induce contractions of the prefilled bladder with a complete draining of the bladder throughout the whole perfusion period.
  • CONCLUSIONS: We could demonstrate that this perfusion system was able to preserve the pig bladder in a functional condition, appropriate for the study of physiological questions.
  • [MeSH-major] Models, Animal. Muscle Contraction / physiology. Muscle, Smooth / physiology. Urinary Bladder / physiology

  • Hazardous Substances Data Bank. CARBACHOL CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17638308.001).
  • [ISSN] 0733-2467
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholinergic Agonists; 8Y164V895Y / Carbachol
  •  go-up   go-down


50. Masuda H, Ichiyanagi N, Yokoyama M, Sakai Y, Kihara K, Chancellor MB, de Groat WC, Yoshimura N: Muscarinic receptor activation in the lumbosacral spinal cord ameliorates bladder irritation in rat cystitis models. BJU Int; 2009 Nov;104(10):1531-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muscarinic receptor activation in the lumbosacral spinal cord ameliorates bladder irritation in rat cystitis models.
  • OBJECTIVE: To investigate whether activation of spinal cholinergic pathways affects bladder activity in rats with chemical cystitis induced by acetic acid (AA) and cyclophosphamide (CYP).
  • MATERIALS AND METHODS: The effects of intrathecal (i.t.) application of neostigmine as an acetylcholine esterase (AChE) inhibitor, oxotremorine-M (OXO-M) as a muscarinic ACh receptor (mAChR) agonist or epibatidine as a nicotinic AChR (nACHR) agonist with or without atropine as a mAChR antagonist or mecamylamine (MEC) as a nAChR antagonist at the level of L6-S1 spinal cord on C-fibre mediated bladder irritation were examined by using continuous-infusion cystometry (0.1 mL/min) in urethane-anaesthetized female Spraque-Dawley rats.
  • Bladder irritation was induced by intravesical AA (0.25%) or pretreatment with intraperitoneal injection of CYP (150 mg/kg) 24 h before cystometry.
  • In control rats during intravesical saline, the effects of above drugs on the bladder activity were also examined.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19466955.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Muscarinic Agonists; 0 / Nicotinic Agonists; 0 / Receptors, Muscarinic
  •  go-up   go-down


51. Milliken I, Munro NP, Subramaniam R: Cystostomy button for bladder drainage in children. J Urol; 2007 Dec;178(6):2604-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystostomy button for bladder drainage in children.
  • We describe our use of this device to facilitate bladder drainage in children.
  • Cases selected included those with a neuropathic bladder, prune belly syndrome, previous major bladder neck surgery and those unsuitable for Mitrofanoff stoma formation.
  • CONCLUSIONS: Button cystostomy is a safe and effective form of bladder drainage in children.
  • [MeSH-major] Cystostomy / instrumentation. Urinary Retention / surgery

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17945298.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Raspollini MR, Comin CE, Crisci A, Chilosi M: The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung. Pathologica; 2010 Feb;102(1):33-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung.
  • Primary bladder adenocarcinoma accounts for 0.5-2% of all malignant bladder tumours.
  • Literature data indicate the bladder as the second most common site of metastatic genitourinary tumours, with the kidney as the most frequent location.
  • Secondary tumours of the bladder account for about 2.3% of all bladder malignancies encountered in surgical specimens.
  • Herein, we describe an adenocarcinoma deeply infiltrating the bladder wall, with no morphologic features of transitional cell carcinoma, in a patient with a previous diagnosis of primary lung adenocarcinoma, mixed subtype.
  • In this case, the use of a limited immunohistochemical panel including napsin A, a recently described highly sensitive marker for lung adenocarcinoma, GATA3 and S100P, two novel markers of urothelial differentiation, was of crucial importance in differentiating between lung adenocarcinoma metastatic to the bladder and primary bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Aspartic Acid Endopeptidases / metabolism. Biomarkers, Tumor / metabolism. GATA3 Transcription Factor / metabolism. Lung Neoplasms. S100 Proteins / metabolism. Urinary Bladder Neoplasms

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731252.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GATA3 Transcription Factor; 0 / GATA3 protein, human; 0 / S100 Proteins; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


53. Becker A, Astroza G, Quezada N, Riaño C, Urrutia J, Guzman S: [Isolated manifestation of necrotizing vasculitis of the bladder: a case report]. Urologe A; 2008 Oct;47(10):1347-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Isolated manifestation of necrotizing vasculitis of the bladder: a case report].
  • [Transliterated title] Isolierte Manifestation einer nekrotisierenden Vaskulitis an der Harnblase: Ein Fallbericht.
  • Isolated vasculitis involving the bladder is rare.
  • Cytopathological examination of the biopsies showed necrotizing vasculitis of the small bladder vessels, which responded to treatment with steroids and cyclophosphamide.
  • [MeSH-major] Polyarteritis Nodosa / diagnostic imaging. Tomography, X-Ray Computed. Urinary Bladder / blood supply. Urinary Bladder Diseases / diagnostic imaging
  • [MeSH-minor] Anti-Inflammatory Agents / administration & dosage. Biopsy. Cyclophosphamide / administration & dosage. Cystoscopy. Diagnosis, Differential. Drug Therapy, Combination. Hematuria / etiology. Humans. Immunosuppressive Agents / administration & dosage. Male. Middle Aged. Prednisone / administration & dosage

  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2005 Apr;65(4):797 [15833535.001]
  • [Cites] Ann Intern Med. 1983 Mar;98 (3):323-6 [6830074.001]
  • [Cites] Urology. 2006 Dec;68(6):1343.e15-7 [17141833.001]
  • [Cites] Actas Urol Esp. 1994 Jan;18(1):47-50 [7910715.001]
  • [Cites] BMJ. 2000 May 13;320(7245):1325-8 [10807632.001]
  • [Cites] Arthritis Rheum. 1994 Feb;37(2):187-92 [8129773.001]
  • [Cites] Arch Pathol Lab Med. 1998 Oct;122(10):903-6 [9786351.001]
  • [Cites] J Formos Med Assoc. 2006 Feb;105(2):164-7 [16477338.001]
  • [Cites] Arthritis Rheum. 1993 Jun;36(6):857-9 [8099481.001]
  • (PMID = 18516581.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


54. Walker A, Tanner MJ, Husson P, Schuler C, Kogan BA, Buttyan R, Levin RM: Differential expression of vascular endothelial growth factor, and angiopoietin 1 and 2 in functionally divergent experimental rabbit models of bladder hypertrophy. J Urol; 2009 Jun;181(6):2790-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of vascular endothelial growth factor, and angiopoietin 1 and 2 in functionally divergent experimental rabbit models of bladder hypertrophy.
  • PURPOSE: Partial bladder outlet obstruction or ovariectomy with subsequent estrogen replenishment induces bladder hypertrophy in rabbits and yet the functional outcomes of these procedures differ.
  • MATERIALS AND METHODS: Groups of male rabbits underwent sham surgery or partial bladder outlet obstruction for 1 or 2 weeks.
  • Female bladders with ovariectomy plus estrogen had attributes that typified bladder hypertrophy with increased contractile function.
  • CONCLUSIONS: Although these models have similar outcomes with regard to bladder hypertrophy, they have opposite functional outcomes that coincide with compartmental differences in the expression of genes involved in the regulation of angiogenesis.
  • [MeSH-major] Angiopoietin-1 / biosynthesis. Angiopoietin-2 / biosynthesis. Urinary Bladder / metabolism. Urinary Bladder / pathology. Vascular Endothelial Growth Factor A / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375749.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiopoietin-1; 0 / Angiopoietin-2; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


55. Pereira DA, Barroso U Jr, Machado P, Pestana JO, Rosito TE, Pires J, Almeida C, Ortiz V, Macedo A Jr: Effects of urinary tract infection in patients with bladder augmentation and kidney transplantation. J Urol; 2008 Dec;180(6):2607-10; discussion 2610
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of urinary tract infection in patients with bladder augmentation and kidney transplantation.
  • PURPOSE: We evaluated the rate of function decline of the renal allograft in patients with augmented bladder.
  • We also evaluated the prevalence of asymptomatic bacteriuria and urinary tract infection in these patients, and to demonstrate if these findings are predictors of allograft function decline, comparing children who underwent bladder augmentation with a control group.
  • MATERIALS AND METHODS: Among 170 children and adolescents undergoing renal transplantation at our institution 23 (14%) had previously undergone bladder augmentation.
  • RESULTS: Mean followup was 18.0 +/- 13.9 months and 25.2 +/- 14.1 months for the augmented and nonaugmented bladder groups, respectively (p >0.05).
  • The incidence of acute rejection within the first 12 months of kidney transplantation was 9% in the bladder augmentation group and 26% in controls (p >0.05).
  • The rate of urinary tract infection or asymptomatic bacteriuria in the first 12 months after kidney transplantation was higher in the bladder augmentation group (19 patients, 83%) compared to controls (7 patients, 17%, p <0.001).
  • Patients with augmented bladder had a higher number of hospital admissions (14 patients, 61%) compared to the control group (12 patients, 29%, p = 0.004).
  • Despite the higher incidence of urinary tract infection in the augmented bladder group, there was no statistically significant difference in graft function between the groups at 6 months (1.1 +/- 0.3 mg/dl vs 1.0 +/- 0.3 mg/dl) or 12 months (1.0 +/- 0.2 mg/dl vs 1.2 +/- 0.7 mg/dl) after transplantation.
  • CONCLUSIONS: Our study demonstrated that patients with transplanted kidney and augmented bladder had more asymptomatic bacteriuria and urinary tract infections than those without bladder augmentation.
  • [MeSH-major] Bacteriuria / epidemiology. Kidney Transplantation. Postoperative Complications / epidemiology. Urinary Bladder / surgery. Urinary Tract Infections / epidemiology


56. García Mediero JM, Angulo Cuesta J, Luján Galán M, Rodríguez García N, Berenguer Sánchez A: [Smoking habit and superficial bladder tumours' natural history]. Actas Urol Esp; 2007 Apr;31(4):349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Smoking habit and superficial bladder tumours' natural history].
  • [Transliterated title] Efecto del tabaco sobre la evolución de los tumores de vejiga.
  • OBJECTIVES: To disclose the features of bladder cancer in current smokers at diagnosis and to study the differences in recurrence and progression between smokers and non-smokers.
  • PATIENTS & METHODS: 786 consecutive patients with bladder cancer from 1991 to 2004 were studied in a retrospective manner and characteristics of smokers tumours were compared to non smokers.
  • RESULTS: 377 (48%) patients were smokers at diagnosis.
  • We found statistical differences in tumours grade, size and multiplicity ( Chi square, p=0.046, p=0.001 and p=0.12 respectly).
  • CONCLUSIONS: Currents smokers present bigger and higher grade tumors and, more frequently in a multiple fashion at diagnosis than non-smokers.
  • [MeSH-major] Smoking / adverse effects. Urinary Bladder Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Smoking and Youth.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633920.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


57. Moxnes JF, Hausken K: A mathematical model for the proliferation of bacteria in the urinary bladder due to enlarged prostate. Med Hypotheses; 2006;67(6):1391-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mathematical model for the proliferation of bacteria in the urinary bladder due to enlarged prostate.
  • Urinary retention due to enlargement of the prostate (prostate hypertrophy) leads to increased proliferation of bacteria in the bladder.
  • Thus the out flux of the bladder consists of repeatedly small amounts of fluid during a day.
  • A mathematical dynamic model with differential equations is developed for the proliferation of bacteria in the urinary bladder (vesica urinary).
  • The model accounts for how this proliferation is associated with varying amounts of mass of urine within the bladder.
  • The relationships between the proliferation of bacteria within the bladder and the type of urinal out flux from the bladder are examined.
  • The proliferation is shown to depend on the amount of mass of urine and the out flux of urine from the bladder.
  • In the normal situation the bladder is drained successfully which also drains the bacteria.
  • In the abnormal situation the bladder drains only partly.
  • Despite frequent urination, substantial urine mass in the bladder on the average allows bacteria to proliferate and increase in number through time.
  • By determining the parameters for each male, the dynamic model can be used as a powerful tool by which the proliferation of bacteria in the bladder can be studied and controlled by different means.
  • First, try to achieve that the proliferation rate of bacteria in the bladder is as small as possible, e.g. through altering the pH or chemical composition within the bladder.
  • Second, try to achieve that the out flux of urine from the bladder is substantial, through sufficient drinking.
  • Third, try to achieve that the mass of urine in the bladder is as small as possible, through sufficient urination.
  • The intrinsic parameters for each male can be used to pinpoint the actual out flux during a day necessary to keep the number of bacteria in the bladder low.
  • [MeSH-major] Bacteria / growth & development. Models, Theoretical. Prostatic Hyperplasia / physiopathology. Urinary Bladder / microbiology. Urinary Bladder / physiology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860489.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


58. Vicente AM, Castrejón AS, Muñoz AP, Woll PP, García AN: Impact of 18F-FDG PET/CT with retrograde filling of the urinary bladder in patients with suspected pelvic malignancies. J Nucl Med Technol; 2010 Sep;38(3):128-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of 18F-FDG PET/CT with retrograde filling of the urinary bladder in patients with suspected pelvic malignancies.
  • The purpose of this study was to assess the feasibility of selective pelvic PET/CT with retrograde bladder irrigation in evaluating pelvic pathologies.
  • Additional delayed pelvic PET/CT images were acquired with a filled-bladder technique.
  • Ten studies showed pathologic (18)F-FDG uptake in the bladder wall; in 7 of these studies the uptake was found to be true-positive on histopathologic examination.
  • The retrograde filling reduced the interference with physiologic urinary accumulation of (18)F-FDG in patients with possible pelvic lesions; no false-negative results were documented.
  • CONCLUSION: In (18)F-FDG PET studies, retrograde filling of the urinary bladder is recommended to assess bladder wall lesions and malignancies in other pelvic locations.
  • [MeSH-major] Artifacts. Fluorodeoxyglucose F18. Pelvic Neoplasms / radiography. Pelvic Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods. Urinary Bladder

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20807854.001).
  • [ISSN] 1535-5675
  • [Journal-full-title] Journal of nuclear medicine technology
  • [ISO-abbreviation] J Nucl Med Technol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


59. Misawa T, Kamimura M, Kinoshita T, Itoh H, Yuzawa Y, Kitahara J: Neurogenic bladder in patients with cervical compressive myelopathy. J Spinal Disord Tech; 2005 Aug;18(4):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurogenic bladder in patients with cervical compressive myelopathy.
  • We examined the urinary disturbances in 56 consecutive patients with cervical compressive myelopathy using the latest International Continence Society classification.
  • Of the 56 patients with cervical compressive myelopathy, 29 (52%) had some urinary subjective complaints, whereas the remaining 27 (48%) had none.
  • Urologic examination indicated that 8 of these 29 (28%) patients with urinary complaints had urologic disorders other than neurogenic bladder.
  • Of the remaining 21 patients, only 6 (25%) were judged to have neurogenic bladder on urodynamic study.
  • Urodynamic study may be of limited value in diagnosing urinary disturbance in cervical myelopathy.
  • Further, four cases (83%) showed underactive bladder activity in voiding phase, and only one case (17%) showed overactive bladder activity in filling phase.
  • These results were contrary to those of previous studies indicating that cervical compressive myelopathy is associated with overactive bladder activity in filling phase.
  • There were no significant differences in motor or sensory Japanese Orthopedic Association scores between the patients with and without urinary complaints.
  • However, the patients with urinary complaints had significantly longer durations of myelopathy and delayed motor evoked potential latencies than those without urinary complaints.
  • After surgery, 19 of the 21 (90%) patients with urinary complaints showed recovery from urinary disturbance.
  • Operations in patients with cervical myelopathy were also effective against urinary disturbance.
  • Urinary complaints may be an indication for surgical treatment despite the results of urodynamic study.
  • [MeSH-major] Cervical Vertebrae. Spinal Cord Compression / complications. Urinary Bladder, Neurogenic / etiology
  • [MeSH-minor] Evoked Potentials, Motor. Female. Humans. Male. Middle Aged. Reaction Time. Severity of Illness Index. Treatment Outcome. Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / etiology. Urinary Bladder Diseases / physiopathology. Urodynamics. Urologic Diseases / etiology

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16021011.001).
  • [ISSN] 1536-0652
  • [Journal-full-title] Journal of spinal disorders & techniques
  • [ISO-abbreviation] J Spinal Disord Tech
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Gomez-Pinilla PJ, Gomez MF, Hedlund P, Swärd K, Hellstrand P, Camello PJ, Pozo MJ, Andersson KE: Effect of melatonin on age associated changes in Guinea pig bladder function. J Urol; 2007 Apr;177(4):1558-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of melatonin on age associated changes in Guinea pig bladder function.
  • PURPOSE: The incidence of urinary incontinence increases with age but the cause and effect relationship between aging and altered bladder function is poorly understood.
  • We investigated the changes in bladder function evoked by aging and the possible benefits of melatonin treatment on age related bladder disturbances.
  • MATERIALS AND METHODS: Bladder function was assessed using cystometry in conscious, freely moving female guinea pigs.
  • RESULTS: Aging led to increased detrusor activity, as demonstrated by short micturition intervals, decreased bladder capacity and spontaneous contractions during the filling phase.
  • Melatonin treatment improved age induced changes in bladder function.
  • If similar effects can be demonstrated in humans, melatonin treatment may be a new approach to decrease the impact of age related bladder disorders.
  • [MeSH-major] Melatonin / pharmacology. Urinary Bladder / drug effects. Urinary Bladder / physiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELATONIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382778.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] JL5DK93RCL / Melatonin
  •  go-up   go-down


61. Bermejo JL, Sundquist J, Hemminki K: Sex-specific familial risks of urinary bladder cancer and associated neoplasms in Sweden. Int J Cancer; 2009 May 1;124(9):2166-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex-specific familial risks of urinary bladder cancer and associated neoplasms in Sweden.
  • Male gender and a family history of cancer are established risk factors for urinary bladder neoplasms.
  • This study used the latest update of the Swedish Family-Cancer Database, which includes 42,255 bladder cancer patients, to investigate the sex-specific incidences and types of tumors in relatives of bladder cancer patients.
  • Men with parents or siblings affected by lung cancer did not show an increased risk of bladder neoplasms.
  • Brothers showed higher risks than the sons of bladder cancer patients.
  • Men older than 54 years were at an increased risk of bladder cancer only if their fathers or siblings were diagnosed after age 65 years.
  • The present data indicated a limited contribution of smoking to the familial clustering of bladder cancer with other neoplasms.
  • Age-specific results suggested differential risk factors for tumors diagnosed before 50 years of age versus neoplasms detected later in life.
  • [MeSH-major] Genetic Predisposition to Disease. Lung Neoplasms / epidemiology. Lung Neoplasms / genetics. Urinary Bladder Neoplasms / epidemiology. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19117061.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Proctor I, Stoeber K, Williams GH: Biomarkers in bladder cancer. Histopathology; 2010 Jul;57(1):1-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers in bladder cancer.
  • Cancer biomarkers provide an opportunity to diagnose tumours earlier and with greater accuracy.
  • They can also identify those patients most at risk of disease recurrence and predict which tumours will respond to different therapeutic approaches.
  • Such biomarkers will be especially useful in the diagnosis and management of bladder cancer.
  • At present, bladder tumours are diagnosed and followed-up using a combination of cystoscopic examination, cytology and histology.
  • These are not only expensive, but also highly subjective investigations and reveal little about the underlying molecular characteristics of the tumour.
  • In recent years numerous diagnostic and prognostic biomarkers of bladder cancer have been identified.
  • [MeSH-major] Biomarkers, Tumor / analysis. Urinary Bladder Neoplasms / chemistry. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Algorithms. Antigens, Neoplasm / urine. Apoptosis. Cell Cycle. Cell Cycle Proteins / analysis. Cyclins / analysis. Cytodiagnosis / methods. DNA Replication. Gene Expression Profiling. Genes, p53. Humans. In Situ Hybridization, Fluorescence. Ki-67 Antigen / analysis. MAP Kinase Signaling System / genetics. Nuclear Proteins / urine. Prognosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20579130.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Cyclins; 0 / Ki-67 Antigen; 0 / MCM5 protein, human; 0 / Nuclear Proteins; 0 / bladder tumor-associated antigen; 0 / nuclear matrix protein 22
  •  go-up   go-down


63. Singh AV, Franke AA, Blackburn GL, Zhou JR: Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis. Cancer Res; 2006 Feb 1;66(3):1851-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis.
  • A role of dietary bioactive components in bladder cancer prevention is biologically plausible because most substances or metabolites are excreted through the urinary tract and are consequently in direct contact with the mucosa of the bladder.
  • We first determined antigrowth activity of genistein against poorly differentiated 253J B-V human bladder cancer cells in vitro.
  • We also evaluated both genistin, which is a natural form of genistein, and the isoflavone-rich soy phytochemical concentrate (SPC) on the growth and metastasis of 253J B-V tumors in an orthotopic tumor model.
  • Mice treated with genistin and SPC had reduced final tumor weights by 56% (P < 0.05) and 52% (P < 0.05), respectively, associated with induction of tumor cell apoptosis and inhibition of tumor angiogenesis in vivo.
  • In addition, SPC treatment, but not genistin treatment, significantly inhibited lung metastases by 95% (P < 0.01) associated with significant down-regulation of NF-kappaB expression in tumor tissues and reduction of circulating insulin-like growth factor-I levels, suggesting that SPC may contain other bioactive ingredients that have antimetastatic activity.
  • The results from our studies suggest that further clinical investigation should be warranted to apply soy phytochemicals, such as SPC, as a potent prevention regimen for bladder cancer progression.
  • This orthotopic human bladder tumor model also provides a clinically relevant experimental tool for assessing potential preventive activity of other dietary components against bladder tumor growth and metastasis.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GENISTEIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1999 Nov;54(5):823-8 [10565741.001]
  • [Cites] Biochem Pharmacol. 2005 Jan 15;69(2):307-18 [15627483.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):143-53 [12242729.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Sep 25;777(1-2):45-59 [12270199.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1674-7 [12496060.001]
  • [Cites] J Nutr. 2003 Jul;133(7):2262-7 [12840190.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):800-6 [15170660.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):319-23 [15352046.001]
  • [Cites] Cancer Res. 1975 Nov;35(11 Pt. 2):3240-5 [1192400.001]
  • [Cites] J Urol. 1983 Dec;130(6):1083-6 [6644886.001]
  • [Cites] J Biol Chem. 1987 Apr 25;262(12):5592-5 [3106339.001]
  • [Cites] Am J Clin Nutr. 1991 Dec;54(6):1093-100 [1659780.001]
  • [Cites] Hematol Oncol Clin North Am. 1992 Feb;6(1):1-30 [1556044.001]
  • [Cites] Ann Urol (Paris). 1992;26(5):281-93 [1485797.001]
  • [Cites] Clin Chim Acta. 1993 Dec 31;223(1-2):9-22 [8143372.001]
  • [Cites] J Nutr. 1994 Jun;124(6):825-32 [8207540.001]
  • [Cites] Nutr Cancer. 1994;21(2):113-31 [8058523.001]
  • [Cites] J Steroid Biochem Mol Biol. 1995 Jan;52(1):97-103 [7857879.001]
  • [Cites] J Nutr. 1995 Mar;125(3 Suppl):733S-743S [7884559.001]
  • [Cites] J Urol. 1995 Oct;154(4):1532-8 [7658585.001]
  • [Cites] Nutr Cancer. 1995;24(1):1-12 [7491293.001]
  • [Cites] J Biol Chem. 1996 Feb 2;271(5):2746-53 [8576250.001]
  • [Cites] Hinyokika Kiyo. 1995 Dec;41(12):969-77 [8578986.001]
  • [Cites] Nutr Cancer. 1996;26(3):289-302 [8910911.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2916-21 [9230201.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5231-8 [9823337.001]
  • [Cites] Int J Cancer. 1998 Dec 9;78(6):775-82 [9833772.001]
  • [Cites] J Nutr. 1999 Sep;129(9):1628-35 [10460196.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):230-6 [10656454.001]
  • (PMID = 16452247.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK040561; United States / NCI NIH HHS / CA / R01 CA092546; None / None / / P30 DK040561-11; United States / NCI NIH HHS / CA / R03 CA112640-01; United States / NIDDK NIH HHS / DK / P30 DK040561-11; United States / NCI NIH HHS / CA / CA112640-01; United States / NCI NIH HHS / CA / R01 CA 92546; United States / NCI NIH HHS / CA / R03 CA112640; United States / NCI NIH HHS / CA / R01 CA092546-01A2; United States / NCI NIH HHS / CA / CA092546-01A2; United States / NCI NIH HHS / CA / R03 CA 112640
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Isoflavones; 0 / NF-kappa B; 103107-01-3 / Fibroblast Growth Factor 2; 67763-96-6 / Insulin-Like Growth Factor I; DH2M523P0H / Genistein
  • [Other-IDs] NLM/ NIHMS109672; NLM/ PMC2683370
  •  go-up   go-down


64. Fullerton NE, Boyd M, Ross SC, Pimlott SL, Babich J, Kirk D, Zalutsky MR, Mairs RJ: Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. Med Chem; 2005 Nov;1(6):611-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
  • Targeted radiotherapy using radiolabelled meta-iodobenzylguanidine (MIBG) is a promising treatment option for bladder cancer, restricting the effects of radiotherapy to malignant cells thereby increasing efficacy and decreasing morbidity of radiotherapy.
  • We investigated the efficacy of a combined gene therapy and targeted radiotherapy approach for bladder cancer using radiolabelled MIBG.
  • Bladder cancer cells, EJ138, were transfected with a gene encoding the noradrenaline transporter (NAT) under the control of a tumour specific telomerase promoter, enabling them to actively take up radiolabelled MIBG.
  • This resulted in tumour-specific cell kill.
  • However, the alpha-emitter [211At]MABG was, by three orders of magnitude, more effective in causing tumour cell kill than the beta-emitter [131I]MIBG.
  • We conclude that NAT gene transfer combined with the administration of n.c.a.
  • [131I]MIBG or [211At]MABG, is a promising novel treatment approach for bladder cancer therapy.
  • [MeSH-major] 3-Iodobenzylguanidine / therapeutic use. Astatine / therapeutic use. Genetic Therapy / methods. Iodine Radioisotopes / therapeutic use. Radiopharmaceuticals / therapeutic use. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Alpha Particles / therapeutic use. Beta Particles / therapeutic use. Cell Line, Tumor. Cell Survival / drug effects. Combined Modality Therapy / methods. Dose-Response Relationship, Radiation. Humans. Iodates / chemistry. Iodates / therapeutic use. Norepinephrine Plasma Membrane Transport Proteins / biosynthesis. Norepinephrine Plasma Membrane Transport Proteins / genetics. Structure-Activity Relationship. Symporters / biosynthesis. Symporters / genetics. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SODIUM IODATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16787344.001).
  • [ISSN] 1573-4064
  • [Journal-full-title] Medicinal chemistry (Shāriqah (United Arab Emirates))
  • [ISO-abbreviation] Med Chem
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Iodates; 0 / Iodine Radioisotopes; 0 / Norepinephrine Plasma Membrane Transport Proteins; 0 / Radiopharmaceuticals; 0 / Symporters; 0 / sodium-iodide symporter; 35MRW7B4AD / 3-Iodobenzylguanidine; U558PCS5Z9 / sodium iodate; XI595HAL7H / Astatine
  •  go-up   go-down


65. Dozmorov MG, Kropp BP, Hurst RE, Cheng EY, Lin HK: Differentially expressed gene networks in cultured smooth muscle cells from normal and neuropathic bladder. J Smooth Muscle Res; 2007 Apr;43(2):55-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentially expressed gene networks in cultured smooth muscle cells from normal and neuropathic bladder.
  • Neuropathic bladder dysfunction results from abnormal development of the spine, spinal cord injuries, or diseases such as diabetics.
  • Patients with neuropathic bladders often require surgical intervention such as bladder reconstruction to improve incontinence and prevent renal damage.
  • Tissue engineering with ex-vivo cultured bladder cells has been suggested as one means for improving bladder function.
  • However, we previously demonstrated that cultured bladder smooth muscle cells (SMCs) derived from neuropathic bladder exhibit and maintain altered pathologic phenotypes in culture.
  • A total of 18 genes that are differentially expressed between cultured normal and neuropathic bladder SMCs were identified.
  • Of these 17 were up-regulated greater than 2-fold in neuropathic bladder SMCs, six of them along with one gene that was not up-regulated greater than 2-fold in cultured neuropathic bladder SMCs were confirmed and identified by more stringent analysis methods including significance analysis of microarrays, class comparison, and class prediction analyses.
  • Our results further suggest that altered neuropathic bladder SMC phenotypes is stable in the culture environments and that SMCs derived from diseased bladders may not be appropriate for tissue engineering purpose without modification of pathologically altered genes expression.
  • [MeSH-major] Gene Expression Profiling. Muscle, Smooth / metabolism. Muscle, Smooth / physiopathology. Myocytes, Smooth Muscle / metabolism. Urinary Bladder / physiopathology. Urinary Bladder, Neurogenic / physiopathology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598958.001).
  • [ISSN] 0916-8737
  • [Journal-full-title] Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi
  • [ISO-abbreviation] J Smooth Muscle Res
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK056968; United States / NIDDK NIH HHS / DK / DK069808
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


66. Robbins MT, Ness TJ: Footshock-induced urinary bladder hypersensitivity: role of spinal corticotropin-releasing factor receptors. J Pain; 2008 Nov;9(11):991-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Footshock-induced urinary bladder hypersensitivity: role of spinal corticotropin-releasing factor receptors.
  • Stress-induced hyperalgesia (SIH), a common clinical observation associated with multiple painful diseases including functional urinary disorders, presently has no mechanistic explanation.
  • Using a footshock treatment, a classic stressor, to magnify physiological responses in a model of urinary bladder pain, we examined one potential group of mediators of SIH, the corticotropin-releasing factor (CRF)-related neuropeptides.
  • Exposure to a footshock treatment produced bladder hypersensitivity in female Sprague-Dawley rats, manifested as significantly more vigorous visceromotor responses (VMRs) to urinary bladder distension (UBD) compared with rats that were exposed to a non-footshock treatment.
  • This bladder hypersensitivity was significantly attenuated by blocking spinal CRF(2) receptors but not CRF(1) receptors.
  • Surprisingly, neither spinal administration of CRF nor the CRF(1) receptor antagonist antalarmin had an effect on bladder nociceptive responses.
  • The results of the present study not only provide further support for a role of stress in the exacerbation of bladder pain but also implicate spinal urocortins and their endogenous receptor, the CRF(2) receptor, as potential mediators of this effect.
  • PERSPECTIVE: This study presents evidence that spinal urocortins and CRF(2) receptors are involved in stress-induced hypersensitivity related to the urinary bladder.
  • This provides a basis for investigating how urocortins mediate SIH, ultimately leading to more effective treatment options for patients with painful bladder syndromes as well as stress-exacerbated chronic pain.

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comp Neurol. 1999 Dec 20;415(3):285-312 [10553117.001]
  • [Cites] Ann Behav Med. 1997 Summer;19(3):279-86 [9603702.001]
  • [Cites] Ann N Y Acad Sci. 1999 Oct 20;885:312-28 [10816663.001]
  • [Cites] J Urol. 2000 Oct;164(4):1265-9 [10992377.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2843-8 [11226328.001]
  • [Cites] Urology. 2001 Mar;57(3):422-7 [11248609.001]
  • [Cites] Clin Sci (Lond). 2001 Jun;100(6):577-89 [11352772.001]
  • [Cites] Neurosci Lett. 2001 Jun 22;306(1-2):97-100 [11403967.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7570-5 [11416224.001]
  • [Cites] J Neurosci Res. 2001 Dec 15;66(6):1217-25 [11746455.001]
  • [Cites] J Neurosci. 2002 Feb 1;22(3):991-1001 [11826127.001]
  • [Cites] J Psychosom Res. 1998 May;44(5):537-45 [9623874.001]
  • [Cites] Gut. 1998 Jun;42(6):845-9 [9691924.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Mar;288(3):1349-56 [10027877.001]
  • [Cites] Can J Gastroenterol. 1999 Mar;13 Suppl A:18A-25A [10202204.001]
  • [Cites] Behav Brain Res. 1999 Apr;100(1-2):207-15 [10212068.001]
  • [Cites] J Nippon Med Sch. 2004 Dec;71(6):358-9 [15673955.001]
  • [Cites] Neurogastroenterol Motil. 2005 Jun;17(3):415-22 [15916629.001]
  • [Cites] Neurogastroenterol Motil. 2005 Jun;17(3):423-32 [15916630.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G42-53 [15746211.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1533-43 [16285953.001]
  • [Cites] Auton Neurosci. 2005 Dec 30;123(1-2):26-35 [16256445.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 10;341(2):532-40 [16427607.001]
  • [Cites] BMC Urol. 2006;6:2 [16469099.001]
  • [Cites] J Endocrinol. 2006 Apr;189(1):167-78 [16614391.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2006 Jun;290(6):R1697-706 [16439667.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2006 Sep;291(3):R692-703 [16614059.001]
  • [Cites] J Neurosci. 2006 Sep 6;26(36):9142-52 [16957071.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Apr;292(4):R1429-38 [17194724.001]
  • [Cites] Neurogastroenterol Motil. 2007 Sep;19(9):754-60 [17539891.001]
  • [Cites] Physiol Behav. 2007 Aug 15;91(5):544-50 [17521683.001]
  • [Cites] Neurosci Biobehav Rev. 2005;29(4-5):829-41 [15893820.001]
  • [Cites] Trends Neurosci. 2002 Oct;25(10):518-24 [12220880.001]
  • [Cites] Int Arch Allergy Immunol. 2003 Mar;130(3):224-31 [12660427.001]
  • [Cites] Neuroendocrinology. 2003 Jul;78(1):1-11 [12869794.001]
  • [Cites] Endocrinology. 2004 Jan;145(1):43-8 [14576187.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G683-91 [14615283.001]
  • [Cites] J Neuroendocrinol. 2004 May;16(5):411-22 [15117334.001]
  • [Cites] Gut. 2004 Jul;53(7):958-64 [15194643.001]
  • [Cites] Trends Pharmacol Sci. 2004 Nov;25(11):563-8 [15491778.001]
  • [Cites] Am J Reprod Immunol. 2004 Oct;52(4):267-75 [15494048.001]
  • [Cites] Int J Pept Protein Res. 1981 Aug;18(2):113-20 [7309372.001]
  • [Cites] Brain Res. 1982 Aug 5;245(1):97-106 [7116195.001]
  • [Cites] Science. 1982 Oct 8;218(4568):162-5 [6981844.001]
  • [Cites] Life Sci. 1983 Dec 26;33(26):2657-63 [6319846.001]
  • [Cites] Neuropeptides. 1985 Feb;5(4-6):545-8 [2987742.001]
  • [Cites] J Am Acad Dermatol. 1986 Feb;14(2 Pt 1):305-11 [2419375.001]
  • [Cites] Physiol Rev. 1986 Oct;66(4):1091-120 [2876446.001]
  • [Cites] Br Med J (Clin Res Ed). 1987 Feb 28;294(6571):540-3 [3103764.001]
  • [Cites] Endocrinology. 1987 Oct;121(4):1320-8 [3498626.001]
  • [Cites] Physiol Behav. 1987;41(6):635-8 [3441534.001]
  • [Cites] J Neurosci. 1991 Mar;11(3):585-99 [2002354.001]
  • [Cites] J Behav Med. 1991 Feb;14(1):87-96 [2038047.001]
  • [Cites] Pharmacol Rev. 1991 Dec;43(4):425-73 [1775506.001]
  • [Cites] J Behav Med. 1992 Apr;15(2):215-20 [1583681.001]
  • [Cites] J Urol. 1993 Mar;149(3):465-9 [8437248.001]
  • [Cites] Percept Mot Skills. 1995 Apr;80(2):605-6 [7675600.001]
  • [Cites] J Neurosci. 1995 Oct;15(10):6340-50 [7472399.001]
  • [Cites] Nature. 1995 Nov 16;378(6554):287-92 [7477349.001]
  • [Cites] Neurosci Lett. 1995 Aug 25;196(3):185-8 [7501279.001]
  • [Cites] Endocrinology. 1996 May;137(5):2167-70 [8612563.001]
  • [Cites] Neurosci Lett. 1997 May 16;227(2):127-30 [9180220.001]
  • [Cites] J Comp Neurol. 1998 Feb 2;391(1):1-10 [9527535.001]
  • [Cites] Endocrinology. 2000 Jan;141(1):256-63 [10614646.001]
  • (PMID = 18632307.001).
  • [ISSN] 1528-8447
  • [Journal-full-title] The journal of pain : official journal of the American Pain Society
  • [ISO-abbreviation] J Pain
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / 1K99DK080981-01; United States / NIDDK NIH HHS / DK / K99 DK080981; United States / NIDDK NIH HHS / DK / DK080981-01; United States / NIDDK NIH HHS / DK / R00 DK080981; United States / NIDDK NIH HHS / DK / K99 DK080981-01; United States / NIDDK NIH HHS / DK / R01 DK051413; United States / NIDDK NIH HHS / DK / DK51413
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / Pyrimidines; 0 / Pyrroles; 0 / Receptors, Corticotropin-Releasing Hormone; 0 / Urocortins; 0 / antalarmin; 0 / antisauvagine 30; 9015-71-8 / Corticotropin-Releasing Hormone
  • [Other-IDs] NLM/ NIHMS72660; NLM/ PMC2579943
  •  go-up   go-down


67. Lehmann J, Retz M, Sidhu SS, Suttmann H, Sell M, Paulsen F, Harder J, Unteregger G, Stöckle M: Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines. Eur Urol; 2006 Jul;50(1):141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines.
  • Recent studies have also reported a significant antitumor effect of magainin II against various cancer cell lines and tumor mice models.
  • In this study, we evaluated the cytotoxic and antiproliferative potency of magainin II in bladder tumor cells and normal fibroblasts.
  • METHODS: The antiproliferative and cytotoxic effect of magainin II was quantified by colorimetric WST-1-, bromodeoxyuridine (BrdU)-, and lactic dehydrogenase (LDH) assays in three bladder cancer cell lines (RT4, 647V, and 486P) and in the murine fibroblast cell line 3T3 as well as in a primary culture from human fibroblasts.
  • Scanning electron microscopy (SEM) was used to visualize the morphologic effects of magainin II on bladder tumor cells and fibroblasts.
  • RESULTS: Magainin II inhibited cell proliferation of bladder cancer cells in a dose-dependent manner.
  • The average IC50 of magainin II against all bladder cancer cell lines was 198.1 microM (range, 52.4-484.03 microM) for the WST-1 assay and 75.2 microM (range, 31.0-135.3 microM) for the BrdU assay.
  • LDH release was increased in all bladder tumor cell lines in the presence of magainin II, whereas normal fibroblasts showed no cell lysis.
  • SEM demonstrated lethal membrane perforation by peptide pore formation in bladder cancer cells, but not in fibroblasts.
  • CONCLUSION: Magainin II peptide exerts cytotoxic and antiproliferative efficacy by pore formation in bladder cancer cells but has no effect on normal murine or human fibroblasts.
  • Magainin II may offer a novel therapeutic strategy in the treatment of bladder cancer with potentially low cytotoxic effects on normal cells.
  • [MeSH-major] Antimicrobial Cationic Peptides / pharmacology. Antineoplastic Agents / pharmacology. Urinary Bladder Neoplasms / pathology. Xenopus Proteins / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Drug Screening Assays, Antitumor. Humans. Magainins. Microscopy, Electron, Scanning

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16476519.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimicrobial Cationic Peptides; 0 / Antineoplastic Agents; 0 / Magainins; 0 / Xenopus Proteins; 108433-95-0 / magainin 2 peptide, Xenopus
  •  go-up   go-down


68. Dornelas CA, Almeida PR, Nascimento GL, Lima EB, Moraes MO: [Experimental model of Walker 256 carcinosarcoma in rats bladder]. Acta Cir Bras; 2006 Jan-Feb;21(1):38-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experimental model of Walker 256 carcinosarcoma in rats bladder].
  • [Transliterated title] Modelo experimental do carcinossarcoma 256 de Walker em bexiga de ratos.
  • PURPOSE: An animal model to study bladder tumor with Walker 256.
  • METHODS: Bladders rats Wistar was catheterized via urethra and compression lesion of the wall bladder was realized with a little clamping after laparotomy.
  • One total of the 0,3 ml suspension with 3 x 10(5) cels viable of the carcinosarcoma was instilled into each bladder.
  • RESULTS: The index of tumor incidence was 100% and the average of surviving was 14,5 days.
  • CONCLUSION: The model studied was efficient and will can to take subsidy the study experimental in treatment of local invasive bladder cancer.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16491221.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] POR
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


69. Yafi FA, Cury FL, Kassouf W: Organ-sparing strategies in the management of invasive bladder cancer. Expert Rev Anticancer Ther; 2009 Dec;9(12):1765-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ-sparing strategies in the management of invasive bladder cancer.
  • Bladder cancer is the second most common genitourinary malignancy.
  • Radical cystectomy and pelvic lymphadenectomy is the standard of care in the management of muscle-invasive bladder cancer.
  • However, recently, bladder-preservation trials conducted by both single- and multi-institutional groups have gained momentum because of comparable survival and recurrence rates in select patients.
  • Careful patient selection, maximum transurethral resection of bladder tumor, cystoscopic evaluation of response with prompt salvage cystectomy for nonresponders and strict long-term follow-up for complete responders constitute the hallmarks of optimal bladder-preservation protocols.
  • [MeSH-major] Cystectomy / methods. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Combined Modality Therapy. Humans. Lymph Node Excision / methods. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Patient Selection. Salvage Therapy / methods. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954288.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 88
  •  go-up   go-down


70. Li C, Yan RP, Yuan GH, Feng YG, Wang JS, Gao X, Huang YS, Zhou JB, Xie SS: [Characterization of a novel transplantable orthotopic nude mouse model with xenografted human bladder transitional cell tumor (BIU-87)]. Zhonghua Zhong Liu Za Zhi; 2006 Oct;28(10):733-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characterization of a novel transplantable orthotopic nude mouse model with xenografted human bladder transitional cell tumor (BIU-87)].
  • OBJECTIVE: A mouse model of orthotopic bladder cancer simulating its human counterpart is of great importance in preclinical evaluation of new treatment modalities such as immunotxin therapy.
  • The aim of the present study is to establish a novel nude mouse model with xenografted human bladder cancer.
  • METHODS: Single cell suspension of an established human bladder transitional cell carcinoma (TCC) cell line BIU-87 was instilled into nude mouse bladders which were pretreated with mild acid washing.
  • The tumor growth in mouse bladder was assessed weekly by magnetic resonance imaging (MRI).
  • At intervals following implantation and MRI tumor detection, the animals were sacrificed for necropsy, histological examination and immunocytochemical studies.
  • RESULTS: The overall tumor establishment was 92.9% (52/56 mice) at 7 - 36 days, while in the subgroup of animals sacrificed at 12 - 13 days, 40 out of 42 animals (95.2%) developed TCC, the majority of which was superficial.
  • The tumor stages were assessed by gross and histopathology.
  • Immunocytochemistry confirmed that the tumor model maintained the biological and immunological features of BIU-87 cells.
  • The changes seen on MRI images well correlated with the extent of tumor invasion identified by histology.
  • Carcinoma in situ could be detected histologically at 7 - 9 days post-inoculation and progressed into papillary or invasive tumors thereafter.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Animals. Antibodies, Monoclonal / analysis. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Mice. Mice, Nude. Neoplasm Staging. Neoplasm Transplantation. Neoplasms, Experimental / pathology. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17366782.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


71. Babjuk M, Hanus T, Safarík L, Dvorácek J, Pavlík I, Soukup V, Pesl M, Szakacsová M, Dusková J: [Cystectomy in the treatment of bladder cancer]. Cas Lek Cesk; 2007;146(10):751-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cystectomy in the treatment of bladder cancer].
  • Radical cystectomy with pelvic lymphadenectomy and urinary diversion is an important component in the treatment of bladder cancer.
  • It is considered the most important method in the therapy for muscle invasive and selected high-risk non-muscle invasive tumours with excellent local control and high complete remission rate.
  • It consists of complete removal of tumour tissue in the bladder, small pelvis and regional lymph nodes.
  • In males, urinary bladder and prostate are routinely removed; in females, bladder, uterus and anterior vaginal wall are removed.
  • [MeSH-major] Cystectomy. Lymph Node Excision. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Male. Pelvis. Tomography, X-Ray Computed. Urinary Diversion

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18020006.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


72. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED: PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer; 2007 Apr 15;109(8):1499-505
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
  • The role of PD-L1 was evaluated as a mechanism for local stage progression in urothelial carcinoma (UC) of the bladder.
  • METHODS: Using immunohistochemistry, PD-L1 expression was evaluated in a cohort of 280 high-risk UCs of the bladder.
  • PD-L1 was modeled as a predictor of bladder cancer stage using ordinal logistic regression.
  • Other covariates evaluated as potential confounders included age, gender, tumor grade, and lymphocytic infiltration.
  • Further, PD-L1 was evaluated as a potential mechanism of bacillus Calmette-Guerin (BCG) failure in the subset of high-risk nonmuscle-invasive tumors that received this treatment.
  • RESULTS: PD-L1 expression was observed in 7% of pTa, 16% of pT1, 23% of pT2, 30% of pT3/4, and 45% of carcinoma in situ (CIS) tumors.
  • PD-L1 expression was associated with high-grade tumors (odds ratio [OR] = 2.4, P = .009) and tumor infiltration by mononuclear cells (OR = 5.5, P = .004).
  • We observed that the key determinants of stage progression in this cohort were World Health Organization/International Society of Urologic Pathology (WHO/ISUP) high-grade tumor pathology (OR = 4.77, 95% confidence interval [CI]: 2.73-8.34; P < .001) and PD-L1 expression (OR = 2.20, P = .012).
  • PD-L1 expression was found to be extremely abundant in the BCG-induced bladder granulomata in 11 of 12 patients failing BCG treatment.
  • CONCLUSIONS: Collectively, these data indicate that tumor PD-L1 may facilitate localized stage-advancement of UC and attenuate responses to BCG immunotherapy by neutralizing T cells that normally guard against cancer invasion from the epithelium into the bladder musculature.
  • [MeSH-major] Antigens, CD / biosynthesis. Carcinoma, Transitional Cell / metabolism. Carcinoma, Transitional Cell / pathology. Granuloma / metabolism. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Antigens, CD274. Biomarkers, Tumor / analysis. Carcinoma in Situ / immunology. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Disease Progression. Female. Humans. Immunohistochemistry. Immunotherapy. Lymphocytes, Tumor-Infiltrating. Male. Middle Aged. Mycobacterium bovis / immunology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17340590.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / Biomarkers, Tumor; 0 / CD274 protein, human
  •  go-up   go-down


73. Jacobs BL, Lee CT, Montie JE: Bladder cancer in 2010: how far have we come? CA Cancer J Clin; 2010 Jul-Aug;60(4):244-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer in 2010: how far have we come?
  • Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from cancer among men in the United States.
  • Although guidelines assist in treatment, the art of managing bladder cancer, such as the decision to use neoadjuvant chemotherapy and the timing of cystectomy, is still variable.
  • Bladder cancer has a propensity to recur, and with recurrence, a significant number of cases progress, which makes the early detection of high-risk patients imperative.
  • Advances in detection, surveillance, and treatment of bladder cancer are reviewed in this article.
  • [MeSH-major] Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor. Carcinoma / pathology. Cystectomy. Cystoscopy. Diagnostic Imaging. Genetic Markers. Humans. Muscle, Smooth / pathology. Muscle, Smooth / surgery. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Risk Factors. Robotics. Urinary Diversion

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society, Inc.
  • (PMID = 20566675.001).
  • [ISSN] 1542-4863
  • [Journal-full-title] CA: a cancer journal for clinicians
  • [ISO-abbreviation] CA Cancer J Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Genetic Markers
  • [Number-of-references] 232
  •  go-up   go-down


74. Sari A, Uyaroglu MA, Ermete M, Oder M, Girgin C, Dincer C: Microcystic urothelial carcinoma of the urinary bladder metastatic to the penis. Pathol Oncol Res; 2007;13(2):170-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic urothelial carcinoma of the urinary bladder metastatic to the penis.
  • Metastatic spread of primary bladder cancer to the penis is an extremely rare event.
  • Here in we report a case of a penile metastasis from microcystic urothelial carcinoma of urinary bladder, in a 56-year-old man who died 6 months after radical cystoprostatectomy and total penectomy.
  • [MeSH-major] Carcinoma / secondary. Penile Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 1999;9(8):1596-8 [10525873.001]
  • [Cites] Int Urol Nephrol. 1991;23(2):161-7 [1864714.001]
  • [Cites] Urol Int. 1984;39(3):125-42 [6377645.001]
  • [Cites] Urol Int. 2001;66(3):162-3 [11316981.001]
  • [Cites] Urology. 2003 Jul;62(1):145 [12837452.001]
  • [Cites] BMC Cancer. 2004 Dec 03;4:90 [15575962.001]
  • [Cites] Br J Urol. 1997 May;79(5):722-5 [9158509.001]
  • [Cites] Int Urol Nephrol. 2005;37(2):291-3 [16142558.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jul;126(7):859-61 [12088460.001]
  • [Cites] Hum Pathol. 1991 Oct;22(10):948-65 [1842384.001]
  • [Cites] Am J Clin Pathol. 1991 Nov;96(5):635-9 [1951186.001]
  • (PMID = 17607382.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


75. Ye Y, Yang H, Grossman HB, Dinney C, Wu X, Gu J: Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer; 2008 Jun;112(11):2467-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer.
  • METHODS: To test the hypothesis that common sequence variants in the cell cycle control pathway may affect bladder cancer susceptibility, the effects of a panel of 10 potential functional single nucleotide polymorphisms (SNPs) from 7 cell cycle control genes, P53, P21, P27, CDK4, CDK6, CCND1, and STK15, were evaluated on bladder cancer risk in a case-control study of 696 bladder cancer cases and 629 healthy controls.
  • RESULTS: Overall, on individual SNP analysis only individuals with the p53 intron 3 16-bp duplication polymorphism variant allele had a significantly reduced bladder cancer risk (odds ratio [OR] = 0.74, 95% confidence interval [CI], 0.56-0.96).
  • In the CART analysis, smoking status was identified as the most influential factor for bladder cancer susceptibility.
  • CONCLUSIONS: These results suggest that cell cycle genetic polymorphisms may affect bladder cancer predisposition through modulation of host genome stability and confirm the importance of studying gene-gene and gene-environment interactions in bladder cancer risk assessment.
  • [MeSH-major] Cell Cycle / genetics. Cell Cycle Proteins / genetics. Genes, cdc / physiology. Genetic Predisposition to Disease. Genetic Variation / genetics. Polymorphism, Single Nucleotide / genetics. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18361427.001).
  • [ISSN] 1097-0142
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 74880; United States / NCI NIH HHS / CA / CA 91846
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins
  •  go-up   go-down


76. Birder LA, de Groat WC: Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol; 2007 Jan;4(1):46-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of disease: involvement of the urothelium in bladder dysfunction.
  • Although the urinary bladder urothelium has classically been thought of as a passive barrier to ions and solutes, a number of novel properties have been recently attributed to urothelial cells.
  • Localization of afferent nerves next to the urothelium suggests that urothelial cells could be targets for neurotransmitters released from bladder nerves or that chemicals released by urothelial cells could alter afferent nerve excitability.
  • Elucidation of mechanisms that influence urothelial function might provide insights into the pathology of bladder dysfunction.

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Traffic. 2004 Mar;5(3):117-28 [15086788.001]
  • [Cites] Neurosci Lett. 2004 May 6;361(1-3):168-71 [15135920.001]
  • [Cites] Adv Exp Med Biol. 2003;539(Pt B):623-33 [15176316.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):247-53 [15245821.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Aug;287(2):F305-18 [15068973.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11803-8 [15282374.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Nov;287(5):F1084-91 [15251862.001]
  • [Cites] J Anat. 1972 Sep;112(Pt 3):433-55 [4636798.001]
  • [Cites] Biol Rev Camb Philos Soc. 1975 May;50(2):215-46 [1100129.001]
  • [Cites] Infect Immun. 1979 May;24(2):552-7 [37168.001]
  • [Cites] J Urol. 1988 Jul;140(1):203-6 [3379688.001]
  • [Cites] Cell Tissue Res. 1991 Jan;263(1):137-43 [2009546.001]
  • [Cites] Life Sci. 1992;51(23):1777-81 [1435086.001]
  • [Cites] Neurourol Urodyn. 1993;12(1):39-47 [8481729.001]
  • [Cites] Br J Urol. 1995 Feb;75(2):230-5 [7531592.001]
  • [Cites] J Physiol. 1994 Nov 1;480 ( Pt 3):439-48 [7869258.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Jun;278(6):F867-74 [10836974.001]
  • [Cites] J Urol. 2000 Aug;164(2):545-50 [10893641.001]
  • [Cites] Am J Med. 2006 Mar;119(3 Suppl 1):9-15 [16483863.001]
  • [Cites] Eur Urol. 2006 Apr;49(4):644-50 [16426734.001]
  • [Cites] Neuroscience. 2006 May 12;139(2):671-85 [16413132.001]
  • [Cites] Curr Opin Urol. 2006 Jul;16(4):268-72 [16770126.001]
  • [Cites] Int J Urol. 2006 May;13(5):520-3 [16771719.001]
  • [Cites] Br J Pharmacol. 2006 Jul;148(5):565-78 [16751797.001]
  • [Cites] BJU Int. 2006 Aug;98(2):424-9 [16879689.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Sep;15(9):1017-37 [16916270.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37836-43 [17030514.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 Mar;292(3):F1065-72 [17107944.001]
  • [Cites] Nature. 2000 Oct 26;407(6807):1011-5 [11069181.001]
  • [Cites] Trends Pharmacol Sci. 2001 Apr;22(4):182-8 [11282418.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6951-6 [11371611.001]
  • [Cites] J Urol. 2001 Nov;166(5):1951-6 [11586266.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13396-401 [11606761.001]
  • [Cites] J Urol. 2002 Apr;167(4):1876-80 [11912452.001]
  • [Cites] BJU Int. 2002 Jul;90(1):118-29 [12081783.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Aug;283(2):F242-53 [12110507.001]
  • [Cites] Int J Antimicrob Agents. 2002 Jun;19(6):457-60 [12135832.001]
  • [Cites] Nat Neurosci. 2002 Sep;5(9):856-60 [12161756.001]
  • [Cites] J Neurosci. 2002 Sep 15;22(18):8063-70 [12223560.001]
  • [Cites] J Urol. 2002 Nov;168(5):2040-5 [12394704.001]
  • [Cites] Auton Autacoid Pharmacol. 2002 Jun;22(3):133-45 [12452898.001]
  • [Cites] Urology. 2002 Nov;60(5 Suppl 1):13-20; discussion 20-1 [12493344.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 May;284(5):F966-76 [12527557.001]
  • [Cites] Science. 2003 Jul 4;301(5629):105-7 [12843396.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 Sep;285(3):F423-9 [12759226.001]
  • [Cites] J Urol. 2003 Sep;170(3):816-7 [12913706.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 Oct;285(4):F651-63 [12770841.001]
  • [Cites] Physiol Rev. 2004 Apr;84(2):579-621 [15044683.001]
  • [Cites] BJU Int. 2004 Apr;93(6):770-6 [15049988.001]
  • [Cites] Lab Invest. 1996 Aug;75(2):147-56 [8765315.001]
  • [Cites] Scand J Urol Nephrol Suppl. 1995;175:43-53 [8771275.001]
  • [Cites] Adv Neurol. 1997;72:347-64 [8993711.001]
  • [Cites] Nature. 1997 Oct 23;389(6653):816-24 [9349813.001]
  • [Cites] J Physiol. 1997 Dec 1;505 ( Pt 2):503-11 [9423189.001]
  • [Cites] J Urol. 1998 Jun;159(6):1862-6; discussion 1866-7 [9598476.001]
  • [Cites] Am J Physiol. 1998 Aug;275(2 Pt 2):F226-9 [9691011.001]
  • [Cites] J Urol. 1999 Jul;162(1):3-11 [10379728.001]
  • [Cites] J Urol. 2004 Dec;172(6 Pt 1):2261-5 [15538244.001]
  • [Cites] Immunology. 2004 Dec;113(4):427-37 [15554920.001]
  • [Cites] J Urol. 2005 Feb;173(2):625-9 [15643277.001]
  • [Cites] J Physiol. 2005 Feb 1;562(Pt 3):859-71 [15576455.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4393-401 [15569663.001]
  • [Cites] J Urol. 2005 May;173(5):1793-6 [15821589.001]
  • [Cites] Cell Tissue Res. 2005 May;320(2):259-68 [15778856.001]
  • [Cites] J Urol. 2005 Jul;174(1):370-4 [15947692.001]
  • [Cites] Neurochem Int. 2005 Sep;47(4):291-7 [15970360.001]
  • [Cites] J Urol. 2005 Sep;174(3):818 [16093961.001]
  • [Cites] J Clin Invest. 2005 Sep;115(9):2412-22 [16110327.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Jan;290(1):F103-10 [16144967.001]
  • [Cites] Br J Pharmacol. 2006 Jan;147 Suppl 1:S172-81 [16402102.001]
  • [Cites] J Urol. 2006 Jan;175(1):358-64 [16406942.001]
  • [Cites] Andrologia. 2006 Feb;38(1):1-12 [16420236.001]
  • [Cites] Urology. 2006 Feb;67(2):425-30 [16461116.001]
  • [Cites] Br J Pharmacol. 2006 Feb;147 Suppl 2:S80-7 [16465186.001]
  • [Cites] Nat Clin Pract Urol. 2005 Nov;2(11):546-54 [16474598.001]
  • [Cites] Nat Clin Pract Urol. 2005 Jul;2(7):310-1 [16474765.001]
  • [Cites] J Urol. 1999 Dec;162(6):2211-6 [10569621.001]
  • (PMID = 17211425.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK049430-11; United States / NIDDK NIH HHS / DK / R01 DK57284; United States / NIDDK NIH HHS / DK / R01 DK54824; United States / NIDDK NIH HHS / DK / R01 DK057284; United States / NIDDK NIH HHS / DK / R37 DK049430-11; United States / NIDDK NIH HHS / DK / R37 DK054824; United States / NIDDK NIH HHS / DK / R56 DK057284; United States / NIDDK NIH HHS / DK / R01 DK054824; United States / NIDDK NIH HHS / DK / R37 DK049430
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  • [Other-IDs] NLM/ NIHMS299069; NLM/ PMC3119256
  •  go-up   go-down


77. Misseri R, Casale AJ, Cain MP, Rink RC: Alternative uses of dextranomer/hyaluronic acid copolymer: the efficacy of bladder neck injection for urinary incontinence. J Urol; 2005 Oct;174(4 Pt 2):1691-3; discussion 1693-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternative uses of dextranomer/hyaluronic acid copolymer: the efficacy of bladder neck injection for urinary incontinence.
  • PURPOSE: Urinary continence in children with neuropathic bladder and other urological disorders depends on a bladder with adequate low pressure storage capacity and a competent outlet.
  • We evaluated the efficacy of submucosal bladder neck (BN) injection of Dx/H for urethral incontinence in children.
  • Parameters examined include gender, underlying disease, prior BN surgery and means of emptying the bladder.
  • Of the patients 3 achieved dryness after injection, all of whom had catheterizable urinary stomas and two-thirds had undergone bladder augmentations.
  • [MeSH-major] Dextrans / therapeutic use. Hyaluronic Acid / therapeutic use. Urinary Incontinence / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Injections. Male. Retrospective Studies. Treatment Outcome. Urinary Bladder, Neurogenic / complications

  • Genetic Alliance. consumer health - Incontinence.
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16148683.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 30KXI0TVD3 / dextranomer; 9004-61-9 / Hyaluronic Acid; K3R6ZDH4DU / Dextrans
  •  go-up   go-down


78. Eduardo Matheus W, Nardi Pedro R, Maia Oliveira RR, Ferreira U, Rodrigues Netto N Jr: [Is there a place for randomized biopsies in the follow up of superficial transitional cell carcinoma of the urinary bladder?]. Actas Urol Esp; 2005 Oct;29(9):842-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Is there a place for randomized biopsies in the follow up of superficial transitional cell carcinoma of the urinary bladder?].
  • [Transliterated title] Cuál es el valor de la biopsia aleatoria en el seguimiento del carcinoma uroterial superficial de vejiga?
  • INTRODUCTION: Transitional cell carcinoma of the bladder represents a disease of entire urothelial tract.
  • Some authors recommend randomized biopsies as a routine workup, others recommend cystoscopies and urinary cytology as the main part of superficial bladder cancer follow up.
  • PATIENTS AND METHODS: Forty nine patients with superficial bladder cancer were followed up during a ten-year period.
  • Randomized biopsies and urinary cytology were harvested according to the international cancer protocol on bladder cancer.
  • 50 (17.4%) out of 288 cystoscopies with urinary cytology found to be positive to transitional cell carcinoma.
  • Sensitivity and specificity of cystoscopies with urinary cytology were 48% and 86.5% respectively.
  • CONCLUSION: Randomized biopsies did not show to detect more local recurrence or progression when compared to the urinary cytology.
  • Cystoscopies with urinary cytology have good sensitivity and specificity for detection of tumor recurrence during follow up of transitional cell carcinoma.
  • [MeSH-major] Biopsy / methods. Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology


79. Kanofsky JA, Nitti VW: Tolterodine for treatment of overactive bladder. Urol Clin North Am; 2006 Nov;33(4):447-53, viii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tolterodine for treatment of overactive bladder.
  • Tolterodine was developed as an antimuscarinic agent specifically for the treatment of overactive bladder.
  • Initial in vivo studies demonstrated a functional selectivity for the muscarinic receptors in the urinary bladder over the salivary glands, and subsequent clinical trials showed an overall superior tolerability profile compared with other drugs in the same class (ie, oxybutynin).
  • With immediate- and extended-release formulations and sustained clinical efficacy during long-term treatment, tolterodine gas become an important treatment option for the symptoms of overactive bladder.
  • [MeSH-major] Benzhydryl Compounds / therapeutic use. Cresols / therapeutic use. Muscarinic Antagonists / therapeutic use. Phenylpropanolamine / therapeutic use. Urinary Bladder, Overactive / drug therapy

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PHENYLPROPANOLAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011380.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzhydryl Compounds; 0 / Cresols; 0 / Delayed-Action Preparations; 0 / Muscarinic Antagonists; 33RU150WUN / Phenylpropanolamine; 5T619TQR3R / Tolterodine Tartrate
  • [Number-of-references] 31
  •  go-up   go-down


80. Piketty M, Bricou A, Blumental Y, de Carné C, Benifla JL: [Bladder endometriosis and barrenness: diagnostic and treatment strategy]. Gynecol Obstet Fertil; 2008 Sep;36(9):913-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder endometriosis and barrenness: diagnostic and treatment strategy].
  • [Transliterated title] Endométriose vésicale et infertilité: modalités de prise en charge diagnostique et thérapeutique.
  • Deep infiltrating endometriosis is a well-known female disease responsible for chronic pelvic pain, urinary dysfunction, infertility, and altered quality of life.
  • The link between barrenness and endometriosis is well known, but there is no direct link between bladder lesion and infertility.
  • Bladder endometriosis is a deeply infiltrating endometriosis lesion.
  • However, for patient suffering from symptomatic isolated bladder endometriosis, surgical management can be offered in first intention.
  • Isolated bladder injuries due to endometriosis are mostly treated by conservative laparoscopic surgery, after a complete evaluation of endometriosis disease and barrenness by clinical exam and imaging techniques.
  • [MeSH-major] Endometriosis / complications. Infertility, Female / etiology. Reproductive Techniques, Assisted. Ureteral Diseases / complications. Urinary Bladder Diseases / complications


81. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M: Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res; 2006 May 1;12(9):2888-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer.
  • In this study, we evaluated the efficacy of the AT1R antagonist candesartan in bladder cancer.
  • EXPERIMENTAL DESIGN: For the study in vitro, human bladder cancer cells (KU-19-19) were cultured with or without angiotensin II and candesartan.
  • For the study in vivo, a tumor xenograft model was prepared in nude mice using KU-19-19 cells.
  • In mice, candesartan both at doses of 2 and 10 mg/kg/d significantly suppressed tumor growth in mice (35.4% and 33.5% reduction in tumor volume).
  • However, candesartan did not induce apoptosis of cancer cells in the tumor.
  • CONCLUSIONS: Specific blockade of AT1R prevented bladder tumor growth by inhibiting angiogenesis.
  • Because AT1R antagonists are widely used to treat hypertension, and a 2 mg/kg/d dose level of candesartan is clinically achievable, this AT1R antagonist could also be used to treat bladder cancer.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Angiotensin II Type 1 Receptor Blockers / therapeutic use. Benzimidazoles / therapeutic use. Neovascularization, Pathologic / prevention & control. Tetrazoles / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Animals. Cell Division / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Female. Humans. Male. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CANDESARTAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16675585.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Benzimidazoles; 0 / Tetrazoles; S8Q36MD2XX / candesartan
  •  go-up   go-down


82. Nelles JL, Konety BR, Saigal C, Pace J, Lai J, Urologic Diseases in America Project: Urethrectomy following cystectomy for bladder cancer in men: practice patterns and impact on survival. J Urol; 2008 Nov;180(5):1933-6; discussion 1936-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urethrectomy following cystectomy for bladder cancer in men: practice patterns and impact on survival.
  • PURPOSE: The benefit of urethrectomy in patients with bladder cancer who are undergoing cystectomy is controversial.
  • We describe the frequency of urethrectomy by bladder cancer stage and identify clinical characteristics that predict urethrectomy.
  • Patient age, race, number of comorbidities and tumor stage were significant independent predictors of survival.
  • Age, race, stage and comorbidities were independent predictors of overall survival in patients with bladder cancer undergoing cystectomy.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1984 Apr;131(4):657-9 [6708178.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1342-7 [15371837.001]
  • [Cites] J Urol. 2003 Mar;169(3):961-3 [12576822.001]
  • [Cites] BJU Int. 2006 Nov;98(5):1008-11 [17034603.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):729-37 [16826589.001]
  • [Cites] Urology. 2004 Nov;64(5):950-4 [15533484.001]
  • [Cites] J Urol. 1996 Nov;156(5):1615-9 [8863551.001]
  • [Cites] Urology. 2006 Mar;67(3):466-71 [16527559.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Urol. 1990 Jul;144(1):73-5 [2359182.001]
  • [Cites] J Urol. 1991 Dec;146(6):1551-3; discussion 1553-4 [1942339.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] Urol Clin North Am. 1994 Nov;21(4):645-51 [7974896.001]
  • [Cites] J Urol. 2005 Apr;173(4):1163-8 [15758728.001]
  • (PMID = 18801516.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / N01 DK012460; United States / NIDDK NIH HHS / DK / T32 DK007790; United States / NIDDK NIH HHS / DK / T32 DK07790-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS83457; NLM/ PMC2643351
  •  go-up   go-down


83. Zhou M, Reuther AM, Levin HS, Falzarano SM, Kodjoe E, Myles J, Klein E, Magi-Galluzzi C: Microscopic bladder neck involvement by prostate carcinoma in radical prostatectomy specimens is not a significant independent prognostic factor. Mod Pathol; 2009 Mar;22(3):385-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic bladder neck involvement by prostate carcinoma in radical prostatectomy specimens is not a significant independent prognostic factor.
  • The independent prognostic importance of microscopic bladder neck involvement by prostate cancer in radical prostatectomy is questionable.
  • We studied a cohort of 1845 patients to determine the significance of microscopic bladder neck involvement.
  • Bladder neck involvement was defined as prostate cancer present within the coned bladder neck.
  • We further categorized the cases as 'true bladder neck involvement' and 'false bladder neck involvement.
  • ' True bladder neck involvement required prostate cancer within thick smooth muscle bundles without intermixed benign prostatic glands.
  • False bladder neck involvement was characterized by prostate cancer intermixed with benign prostatic glands.
  • Bladder neck involvement was analyzed in relation to preoperative serum prostate-specific antigen (PSA) level, extraprostatic extension, seminal vesicle involvement, positive surgical margin, lymph node involvement, radical prostatectomy Gleason score, and tumor volume.
  • Of the 90 patients (4.9%) with microscopic bladder neck involvement, 63 were further classified as true bladder neck involvement and 27 as false bladder neck involvement.
  • In univariate model, both types of bladder neck involvement (P<0.001), true (P<0.001), and false (P=0.040), were significantly associated with increased PSA-recurrence risk compared to bladder neck negative cases.
  • In multivariate model the PSA-recurrence relative risk associated with bladder neck involvement (true or false) was not a significant independent prognostic factor.
  • The time to biochemical recurrence in patients with bladder neck involvement was similar to that of pT2 with positive surgical margin or pT3a with negative surgical margin patients (Kaplan-Meier curves).
  • Bladder neck involvement was associated with other adverse pathologic features, but was not an independent predictor of PSA recurrence.
  • In view of the previous and current data, the staging system for bladder neck involvement should be revised and patients may be best categorized as having pT3a disease.
  • [MeSH-major] Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Prostate-Specific Antigen / blood. Prostatectomy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19043400.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


84. Mondul AM, Weinstein SJ, Männistö S, Snyder K, Horst RL, Virtamo J, Albanes D: Serum vitamin D and risk of bladder cancer. Cancer Res; 2010 Nov 15;70(22):9218-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum vitamin D and risk of bladder cancer.
  • Vitamin D may protect against several cancers, but data about the association between circulating vitamin D and bladder cancer are limited.
  • Within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, a randomized controlled trial conducted to determine the effects of α-tocopherol and β-carotene supplements on cancer incidence in male smokers, 250 bladder cancer cases were randomly sampled by month of blood collection.
  • Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) of bladder cancer by a priori categories of baseline serum 25-hydroxyvitamin D [25(OH)D; i.e., <25, 25 to <37.5, 37.5 to <50, ≥50 nmol/L] and by season-specific quartiles.
  • After multivariable adjustment, we found that lower 25(OH)D was associated with a statistically significantly increased risk of bladder cancer (versus ≥50 nmol/L; <25 nmol/L: OR, 1.73; 95% CI, 1.03-2.91; 25 to <37.5 nmol/L: OR, 1.81; 95% CI, 1.05-3.14; 37.5 to <50 nmol/L: OR, 1.76; 95% CI, 1.02-3.02; P trend=0.04).
  • In this prospective study of male smokers, lower serum 25(OH)D was associated with an increased risk of bladder cancer.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VITAMIN E .
  • Hazardous Substances Data Bank. BETA-CAROTENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AACR.
  • [Cites] BJU Int. 2007 Apr;99(4):933-7 [17378851.001]
  • [Cites] Cancer Causes Control. 2005 Mar;16(2):83-95 [15868450.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):25-36 [18815914.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):12-20 [19054893.001]
  • [Cites] Am J Clin Nutr. 2008 Dec;88(6):1519-27 [19064511.001]
  • [Cites] Ann Epidemiol. 2009 Feb;19(2):73-8 [18329892.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] BMJ. 2010;340:b5500 [20093284.001]
  • [Cites] Cancer Causes Control. 2010 Apr;21(4):609-19 [20043202.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):58-69 [20562184.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):81-93 [20562185.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):70-80 [20562186.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):47-57 [20562187.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):10-20 [20562188.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):36-46 [20562189.001]
  • [Cites] Am J Epidemiol. 2010 Jul 1;172(1):94-106 [20562192.001]
  • [Cites] J Urol. 2001 Jan;165(1):253-8 [11125420.001]
  • [Cites] Am J Epidemiol. 2000 Dec 15;152(12):1145-53 [11130620.001]
  • [Cites] Bone. 2002 May;30(5):771-7 [11996918.001]
  • [Cites] Acta Oncol. 2002;41(4):381-8 [12234031.001]
  • [Cites] Am J Clin Nutr. 2004 Mar;79(3):362-71 [14985208.001]
  • [Cites] Clin Biochem. 2004 Oct;37(10):867-74 [15369717.001]
  • [Cites] Ann Epidemiol. 1994 Jan;4(1):1-10 [8205268.001]
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • (PMID = 20978193.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / CCR NIH HHS / RC / N01-RC-45035; United States / PHS HHS / / HHSN261201000006C; United States / NCI NIH HHS / CP / HHSN261201000006C; United States / CCR NIH HHS / RC / N01-RC-37004; United States / Intramural NIH HHS / / Z99 CA999999; United States / NCI NIH HHS / CN / N01-CN-45165; United States / CCR NIH HHS / RC / N01RC37004; United States / NCI NIH HHS / CN / N01 CN045165
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 01YAE03M7J / beta Carotene; 1406-16-2 / Vitamin D; 64719-49-9 / 25-hydroxyvitamin D; H4N855PNZ1 / alpha-Tocopherol
  • [Other-IDs] NLM/ NIHMS240141; NLM/ PMC2982924
  •  go-up   go-down


85. Chin WW, Lau WK, Bhuvaneswari R, Heng PW, Olivo M: Chlorin e6-polyvinylpyrrolidone as a fluorescent marker for fluorescence diagnosis of human bladder cancer implanted on the chick chorioallantoic membrane model. Cancer Lett; 2007 Jan 8;245(1-2):127-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chlorin e6-polyvinylpyrrolidone as a fluorescent marker for fluorescence diagnosis of human bladder cancer implanted on the chick chorioallantoic membrane model.
  • The use of fluorescence diagnosis as a modern cancer diagnostic modality is rapidly gaining importance in the field of urology.
  • Therefore, the search for specific fluorescent dyes with high sensitivity and specificity for bladder cancer is constantly being sought after.
  • The aim of this study is to investigate the use of a new formulation consisting a mixture of chlorin e6 and polyvinylpyrrolidone (Ce6-PVP) for the detection of human bladder cancer cells (MGH) implanted on the chick chorioallantoic membrane (CAM) model.
  • Uptake kinetics studies were quantitatively determined for both systemic and topical administrations of Ce6-PVP to the normal CAM as well as the MGH human bladder tumor implanted on CAM using fluorescence imaging technique.
  • Ce6-PVP was found to localize selectively in the xenografted bladder tumor in contrast to the CAM tissue.
  • In conclusion, the Ce6-PVP formulation appeared to have the potential as a fluorescent marker for fluorescence diagnosis of human bladder cancer.
  • [MeSH-major] Chorioallantoic Membrane / metabolism. Fluorescence. Porphyrins / pharmacokinetics. Povidone / pharmacokinetics. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Animals. Cell Line, Tumor. Chick Embryo. Chickens. Diagnostic Imaging / methods. Fluorometry / methods. Humans. Kinetics. Neoplasm Transplantation. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. POLYVINYLPYRROLIDONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16516376.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Porphyrins; 19660-77-6 / chlorin e6; 9003-39-8 / Povidone
  •  go-up   go-down


86. Kubota Y, Hashitani H, Shirasawa N, Kojima Y, Sasaki S, Mabuchi Y, Soji T, Suzuki H, Kohri K: Altered distribution of interstitial cells in the guinea pig bladder following bladder outlet obstruction. Neurourol Urodyn; 2008;27(4):330-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered distribution of interstitial cells in the guinea pig bladder following bladder outlet obstruction.
  • AIMS: We investigated the effects of bladder outlet obstruction (BOO) on the distribution of interstitial cells (ICs) in the guinea-pig bladder.
  • METHODS: Bladder overactivity of BOO animals was validated with urodynamic studies.
  • CONCLUSIONS: These results demonstrated the increased population of ICs in the BOO guinea-pig model for the first time, and suggest that the altered distribution of ICs may contribute to the pathophysiology of bladder overactivity.
  • [MeSH-major] Muscle, Smooth / pathology. Urinary Bladder / pathology. Urinary Bladder Neck Obstruction / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc
  • (PMID = 17724735.001).
  • [ISSN] 0733-2467
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Vimentin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


87. Martov AG, Chernyshev IV, Sysoev PA, Gushchin BL, Shapovalov VV, Kozlov VV, Kornienko SI: [Endoscopic operations in invasive cancer of the urinary bladder]. Urologiia; 2005 Mar-Apr;(2):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic operations in invasive cancer of the urinary bladder].
  • Long-term results of conservative treatment of 153 patients with invasive cancer of the urinary bladder were studied retrospectively.
  • GI, G2 and G3 tumors were registered in 104 (68%), 35 (24%) and 12 (8%) cases, respectively.
  • In the patients with a small invasive tumor of the urinary bladder subjected to surgery alone (TUR-vaporization), overall 5-year survival was 70.4%.
  • In patients with advanced cancer of the urinary bladder who had received curative radiotherapy in case of superficial residual tumor had TUR-vaporization of the urinary bladder overall 5-year survival was 76.5%.
  • Thus, the conclusion is that transurethral electrosurgery in conservative therapy of patients with invasive cancer of the urinary bladder is a promising approach.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Endoscopy / methods. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Electrosurgery. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15989025.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


88. Mitra AP, Bartsch CC, Cote RJ: Strategies for molecular expression profiling in bladder cancer. Cancer Metastasis Rev; 2009 Dec;28(3-4):317-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies for molecular expression profiling in bladder cancer.
  • Carcinoma of the urinary bladder involves alterations in multiple cellular pathways that dictate the pathology of the disease and clinical outcome of the patient.
  • This includes alterations in regulation of the cell cycle, apoptotic mechanisms, signal transduction and tumor angiogenesis.
  • A combination of both these approaches is needed for the identification and validation of robust marker panels of potential clinical importance in bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / genetics. Gene Expression Profiling / methods. Neoplasm Proteins / genetics. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Apoptosis / genetics. Biomarkers, Tumor / genetics. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Cell Cycle / genetics. Genetic Association Studies. Humans. Metabolic Networks and Pathways / genetics. Neovascularization, Pathologic / genetics. Prognosis. Reproducibility of Results. Signal Transduction / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19997771.001).
  • [ISSN] 1573-7233
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Number-of-references] 74
  •  go-up   go-down


89. Grol S, van Koeveringe GA, de Vente J, van Kerrebroeck PE, Gillespie JI: Regional differences in sensory innervation and suburothelial interstitial cells in the bladder neck and urethra. BJU Int; 2008 Sep;102(7):870-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional differences in sensory innervation and suburothelial interstitial cells in the bladder neck and urethra.
  • OBJECTIVE: To identify and characterize possible structural specialisations in the wall of the lower urinary tract (LUT) in the region of the bladder urethral junction (BUJ), with the specific objective of identifying regional variations in sensory nerve fibres and interstitial cells (ICs).
  • MATERIALS AND METHODS: The bladder base and urethra was removed from five male guinea pigs killed by cervical dislocation.
  • RESULTS: The wall of the LUT in the region immediately between the bladder base and the urethra, the BUJ, differed in its cellular composition relative to the adjacent areas.
  • One of the major current challenges in functional urology is to understand the relationships between these novel structures and overall bladder and urethral function.
  • [MeSH-major] Nerve Fibers / physiology. Urethra / innervation. Urinary Bladder / innervation

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537955.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vimentin
  •  go-up   go-down


90. Lin WY, Li S, Leggett R, Strassner J, Sokol R, Schuler C, Juan YS, Javed Z, Kogan B, Levin RM, Mannikarottu A: Estrogen administration attenuates bladder outlet obstruction induced oxidative stress in the female rabbit. Neurourol Urodyn; 2009;28(1):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen administration attenuates bladder outlet obstruction induced oxidative stress in the female rabbit.
  • AIMS: Estrogen administration to female rabbits induces a functional hypertrophy of the bladder.
  • The aim of this study was to investigate whether supplementation of estrogen in the female rabbit with partial bladder outlet obstruction (PBOO) would affect the severity of bladder dysfunction.
  • [MeSH-major] Antioxidants / administration & dosage. Estradiol / administration & dosage. Estrogens / administration & dosage. Muscle Contraction / drug effects. Oxidative Stress / drug effects. Urinary Bladder / drug effects. Urinary Bladder Neck Obstruction / drug therapy

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. CARBACHOL CHLORIDE .
  • Hazardous Substances Data Bank. L-TYROSINE .
  • Hazardous Substances Data Bank. POTASSIUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18671298.001).
  • [ISSN] 1520-6777
  • [Journal-full-title] Neurourology and urodynamics
  • [ISO-abbreviation] Neurourol. Urodyn.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R0-1-DK 067114
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Cholinergic Agonists; 0 / Estrogens; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; 4TI98Z838E / Estradiol; 660YQ98I10 / Potassium Chloride; 8L70Q75FXE / Adenosine Triphosphate; 8Y164V895Y / Carbachol; EC 1.15.1.1 / Superoxide Dismutase; EC 2.3.1.6 / Choline O-Acetyltransferase
  •  go-up   go-down


91. Hashimoto T, Nagabukuro H, Doi T: Effects of the selective acetylcholinesterase inhibitor TAK-802 on the voiding behavior and bladder mass increase in rats with partial bladder outlet obstruction. J Urol; 2005 Sep;174(3):1137-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of the selective acetylcholinesterase inhibitor TAK-802 on the voiding behavior and bladder mass increase in rats with partial bladder outlet obstruction.
  • PURPOSE: We examined the effects of the selective acetylcholinesterase (AChE) inhibitor TAK-802 on voiding behavior and residual urine volume in rats with partial bladder outlet obstruction (BOO) vs rats treated with the nonselective AChE inhibitor distigmine and the muscarinic agonist bethanechol.
  • In addition, the effect of repeat doses of TAK-802 on the bladder mass increase associated with BOO was also examined.
  • Subsequently the volume of urine retained in the bladder (residual urine) was measured.
  • In another experiment bladder weight in rats with BOO was measured after early repeat doses of TAK-802.
  • In addition, bladder weight in the control BOO group was greater (approximately 2.2-fold) than that in the sham operated group and early repeat administration of TAK-802 prevented the bladder mass increase.
  • The prevention of a bladder mass increase by TAK-802 treatment may be attributable to its effect on restoring voiding.
  • [MeSH-major] Cholinesterase Inhibitors / pharmacology. Pyrroles / pharmacology. Quinolones / pharmacology. Urinary Bladder / drug effects. Urinary Bladder Neck Obstruction / physiopathology. Urodynamics / drug effects

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094081.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 8-(3-(1-((3-fluorophenyl)methyl)-4-piperidinyl)-1-oxopropyl)-1,2,5,6-tetrahydro-4H-pyrrolo(3,2,1-ij)quinolin-4-one; 0 / Cholinesterase Inhibitors; 0 / Muscarinic Agonists; 0 / Pyridinium Compounds; 0 / Pyrroles; 0 / Quinolones; 004F72P8F4 / Bethanechol; T940307O7B / distigmine
  •  go-up   go-down


92. Kalorin CM, Belarmino J, Mian B, De E: Complete eversion of the urinary bladder: presentation, review, and algorithm for management. Obstet Gynecol; 2009 Feb;113(2 Pt 2):496-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete eversion of the urinary bladder: presentation, review, and algorithm for management.
  • BACKGROUND: Complete eversion of the urinary bladder is a rare problem that presents a serious management challenge.
  • We describe our experience with bladder eversion and present an algorithm for treatment.
  • CASE: An elderly, multiparous woman presented with complete bladder eversion after partial colpocleisis.
  • Her bladder was reduced by a combined suprapubic and perineal approach with cystopexy to the anterior abdominal wall.
  • CONCLUSION: Multiparous postmenopausal women appear to be at highest risk for complete bladder eversion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155933.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


93. Singh S, Robinson M, Ismail I, Saha M, Auer H, Kornacker K, Robinson ML, Bates CM, McHugh KM: Transcriptional profiling of the megabladder mouse: a unique model of bladder dysmorphogenesis. Dev Dyn; 2008 Jan;237(1):170-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional profiling of the megabladder mouse: a unique model of bladder dysmorphogenesis.
  • Homozygotic mgb mice (mgb-/-) develop lower urinary tract obstruction in utero due to a lack of bladder smooth muscle differentiation.
  • In conclusion, the results of this study indicate that the molecular pathways controlling normal smooth muscle development are severely altered in mgb-/- bladders, and provide the first evidence that Urp may play a critical role in bladder smooth muscle development.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069694.001).
  • [ISSN] 1058-8388
  • [Journal-full-title] Developmental dynamics : an official publication of the American Association of Anatomists
  • [ISO-abbreviation] Dev. Dyn.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK055791; United States / NIDDK NIH HHS / DK / R01-DK70907; United States / NEI NIH HHS / EY / R01-EY12995
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Hormones; 0 / Serum Response Factor; 0 / urotensin II-related peptide, mouse
  •  go-up   go-down


94. Zimichev AA, Prianichnikova MB, Maklakov VN: [Cancer of the urinary bladder: prognosis of the outcome]. Urologiia; 2009 May-Jun;(3):52-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cancer of the urinary bladder: prognosis of the outcome].
  • It is shown that the results of organ-salvage treatment of bladder cancer depend on epidemiological, clinical and morphological characteristics of the tumor.
  • A correlation-regression analysis revealed a complex of the most significant independent prognostic factors which were used for design of a mathematic model of urinary bladder cancer prognosis and computer program for assessment of survival of patients with bladder cancer.
  • This method can be applied for development of measures of tertiary prophylaxis of cancer of the bladder.
  • [MeSH-major] Models, Biological. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673123.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


95. Somuncu S, Rizalar R, Aritürk E, Bernay F: Autorevascularization of the testicle and spermatic vessels by bladder pedicle flap: an experimental study. J Pediatr Surg; 2005 Aug;40(8):1295-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autorevascularization of the testicle and spermatic vessels by bladder pedicle flap: an experimental study.
  • PURPOSE: The aim of the study was to investigate revascularization of the testicle through its own tissue and spermatic vessels by a bladder pedicle flap in rabbits.
  • The FS procedure and revascularization of the testicle by a bladder pedicle flap were applied to the right testicles in 10 animals (FSO group).
  • CONCLUSION: We suppose that the surgical model of revascularization of the testicle through its own tissue and spermatic vessels by a bladder pedicle flap can be an alternative to the FS procedure in abdominal and high canalicular undescended testicles.
  • [MeSH-major] Neovascularization, Physiologic / physiology. Spermatic Cord / blood supply. Surgical Flaps / blood supply. Testis / blood supply. Urinary Bladder / transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080935.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] A0730CX801 / Sodium Pertechnetate Tc 99m
  •  go-up   go-down


96. Hashim H, Al Mousa R: Management of fluid intake in patients with overactive bladder. Curr Urol Rep; 2009 Nov;10(6):428-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of fluid intake in patients with overactive bladder.
  • Overactive bladder (OAB) syndrome is a prevalent condition that affects millions of people worldwide.
  • Conservative treatment is first-line therapy for OAB sufferers, including lifestyle interventions, bladder training, and pelvic floor exercises.
  • [MeSH-major] Drinking. Urinary Bladder, Overactive / therapy

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1996 Sep;101(3):281-90 [8873490.001]
  • [Cites] Neurourol Urodyn. 2006;25(3):293 [28817211.001]
  • [Cites] J Obstet Gynaecol. 2001 Sep;21(5):528-9 [12521814.001]
  • [Cites] Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5 [17049716.001]
  • [Cites] J Urol. 2006 Jan;175(1):191-4; discussion 194-5 [16406907.001]
  • [Cites] Neurourol Urodyn. 2002;21(2):167-78 [11857671.001]
  • [Cites] Public Health Nutr. 2004 Oct;7(7):885-91 [15482614.001]
  • [Cites] J Community Health Nurs. 1996;13(3):179-86 [8916607.001]
  • [Cites] Urology. 2001 Jun;57(6):1044-50 [11377301.001]
  • [Cites] Br J Nurs. 2002 Apr 25-May 8;11(8):560-5 [11979209.001]
  • [Cites] Am J Manag Care. 2000 Jul;6(11 Suppl):S574-9 [11183900.001]
  • [Cites] Urology. 2004 Mar;63(3):461-5 [15028438.001]
  • [Cites] Urology. 2003 Jun;61(6):1123-8 [12809878.001]
  • [Cites] J Wound Ostomy Continence Nurs. 1999 Nov;26(6):312-3, 315-9 [10865616.001]
  • [Cites] Arch Gerontol Geriatr. 2006 Nov-Dec;43(3):319-26 [16457897.001]
  • [Cites] BJU Int. 2003 Jul;92(1):69-77 [12823386.001]
  • [Cites] Eur Urol. 2006 Nov;50(5):1050-7 [16753252.001]
  • [Cites] Obstet Gynecol. 2000 Jul;96(1):85-9 [10862848.001]
  • [Cites] BJU Int. 2008 Jul;102(1):62-6 [18284414.001]
  • [Cites] Br J Urol. 1970 Dec;42(6):714-23 [5491923.001]
  • [Cites] Am J Manag Care. 2002 Dec;8(19 Suppl):S608-15 [12516955.001]
  • [Cites] Br J Urol. 1990 Dec;66(6):613-4 [2265333.001]
  • [Cites] Neurourol Urodyn. 1993;12(1):1-7 [8481726.001]
  • [Cites] BJOG. 2003 Mar;110(3):247-54 [12628262.001]
  • [Cites] J Urol. 2005 Jul;174(1):187-9 [15947624.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(1):22-8 [10207763.001]
  • [Cites] Obstet Gynecol. 1996 May;87(5 Pt 1):715-21 [8677073.001]
  • (PMID = 19863853.001).
  • [ISSN] 1534-6285
  • [Journal-full-title] Current urology reports
  • [ISO-abbreviation] Curr Urol Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Lundin J, Söderhäll C, Lundén L, Hammarsjö A, White I, Schoumans J, Läckgren G, Kockum CC, Nordenskjöld A: 22q11.2 microduplication in two patients with bladder exstrophy and hearing impairment. Eur J Med Genet; 2010 Mar-Apr;53(2):61-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 22q11.2 microduplication in two patients with bladder exstrophy and hearing impairment.
  • Bladder exstrophy is a congenital malformation of the bladder and urethra.
  • A few bladder exstrophy patients have been described to carry chromosomal aberrations.
  • We have performed array-CGH analysis of 36 Swedish bladder exstrophy patients.
  • The analysis revealed a similar and approximately 3 Mb duplication, consistent with the recently described 22q11.2 microduplication syndrome, in two unrelated cases with bladder exstrophy and hearing impairment.
  • Subsequent MLPA analysis of this chromosomal region in 33 bladder exstrophy patients did not reveal any deletion/duplication within this region.
  • This is the first report of 22q11.2 microduplication associated with bladder exstrophy and hearing impairment.
  • [MeSH-major] Bladder Exstrophy / genetics. Chromosomes, Human, Pair 22. Gene Duplication. Hearing Loss / genetics

  • Genetic Alliance. consumer health - Exstrophy of the Bladder.
  • Genetic Alliance. consumer health - Hearing Impairment.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20045748.001).
  • [ISSN] 1878-0849
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


98. Thomas JC, Oottamasathien S, Makari JH, Honea L, Sharif-Afshar AR, Wang Y, Adams C, Wills ML, Bhowmick NA, Adams MC, Brock JW 3rd, Hayward SW, Matusik RJ, Pope JC 4th: Temporal-spatial protein expression in bladder tissue derived from embryonic stem cells. J Urol; 2008 Oct;180(4 Suppl):1784-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal-spatial protein expression in bladder tissue derived from embryonic stem cells.
  • PURPOSE: Identifying developmental proteins could lead to markers of bladder progenitor cells, which could be used to investigate bladder diseases.
  • We recently reported a novel embryonic stem cell model in which to study differential protein expression patterns during bladder development.
  • Heterospecific recombinant xenografts were created by combining embryonic stem cells plus embryonic bladder mesenchyma and placed beneath the renal capsule of mouse hosts.
  • CONCLUSIONS: We report the temporal spatial expression of various genes in early bladder development.
  • This suggests that some proteins may be potential markers of bladder progenitor cells.
  • Characterizing these markers may potentially identify bladder progenitor cells that have been directed toward a lineage path destined to become urothelial cells.
  • Ultimately these multipotential progenitor cells could be isolated and used to study and treat diseases that affect the bladder.
  • [MeSH-major] Embryonic Stem Cells / metabolism. Gene Expression Regulation, Developmental / physiology. Urinary Bladder / embryology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721943.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Foxa1 protein, mouse; 0 / Foxa2 protein, mouse; 0 / Hepatocyte Nuclear Factor 3-alpha; 0 / Membrane Glycoproteins; 0 / Uroplakin III; 135845-92-0 / Hepatocyte Nuclear Factor 3-beta
  •  go-up   go-down


99. Bivalacqua TJ, Loeb S, Pierorazio PM, Schoenberg MP, Partin AW, Guzzo TJ: Is prostate-specific antigen surveillance necessary in men with benign prostate pathology following radical cystoprostatectomy for bladder cancer? Urol Int; 2010;85(4):466-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is prostate-specific antigen surveillance necessary in men with benign prostate pathology following radical cystoprostatectomy for bladder cancer?
  • BACKGROUND: Radical cystoprostatectomy (RCP) remains the gold standard for the treatment of muscle-invasive bladder cancer.
  • There are limited data regarding the clinical impact and detection of PSA following complete prostatectomy or the need to monitor serum PSA in patients with benign prostate pathology at time of RCP.
  • The purpose of our study was to analyze the postoperative PSA characteristics of men without prostate cancer who underwent a RCP for bladder cancer.
  • METHODS: The demographic, clinical and pathologic data were reviewed on 138 men who underwent RCP for bladder cancer from 1994 to 2008.
  • CONCLUSIONS: Serum PSA should remain undetectable for men with benign prostate pathology undergoing complete prostatectomy at the time of RCP.
  • Elevated serum PSA following complete RCP in men with bladder cancer and pathologically confirmed benign prostate findings is rare.
  • If the serum PSA is undetectable 3 months after RCP with benign prostate pathology, there is no need for continued PSA monitoring.
  • [MeSH-major] Cystectomy. Prostate / surgery. Prostate-Specific Antigen / blood. Prostatectomy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Baltimore. Humans. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Time Factors. Treatment Outcome


100. Kajbafzadeh AM, Moosavi S, Tajik P, Arshadi H, Payabvash S, Salmasi AH, Akbari HR, Nejat F: Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology; 2006 Nov;68(5):1091-6; discussion 1096-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele.
  • OBJECTIVES: To evaluate the efficacy of botulinum toxin A in the treatment of children with detrusor hyperreflexia caused by myelomeningocele and the effects of this treatment on neuropathic bladder and bowel dysfunction.
  • In each patient, urinary incontinence grade and improvement in parameters of interest in the evaluation of bowel dysfunction were assessed before and 4 months after injection.
  • Conventional urodynamic studies to determine maximal bladder capacity and maximal detrusor pressure and voiding cystoureterography were also performed.
  • The average maximal bladder capacity increased from 102.8 +/- 6.3 mL to 270.2 +/- 9.5 mL (P <0.01).
  • CONCLUSIONS: Botulinum toxin A appears to be a safe, minimally invasive procedure for the management of neuropathic bladder and bowel dysfunction in children with myelomeningocele.
  • [MeSH-major] Botulinum Toxins, Type A / administration & dosage. Fecal Incontinence / drug therapy. Fecal Incontinence / etiology. Meningomyelocele / complications. Urinary Bladder, Neurogenic / drug therapy. Urinary Bladder, Neurogenic / etiology. Urinary Incontinence / drug therapy. Urinary Incontinence / etiology

  • Genetic Alliance. consumer health - Meningomyelocele.
  • MedlinePlus Health Information. consumer health - Botox.
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17113899.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down






Advertisement